{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:06:42Z","timestamp":1790388402858,"version":"4.1.0"},"reference-count":497,"publisher":"Sociedade Brasileira de Cardiologia","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,13]]},"DOI":"10.36660\/abc.20250640","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:06:41Z","timestamp":1763564801000},"source":"Crossref","is-referenced-by-count":11,"title":["Diretriz Brasileira de Dislipidemias e Preven\u00e7\u00e3o da Aterosclerose \u2013 2025"],"prefix":"10.36660","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6304-1673","authenticated-orcid":false,"given":"Fabiana Hanna","family":"Rached","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-5701","authenticated-orcid":false,"given":"Marcio Hiroshi","family":"Miname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-664X","authenticated-orcid":false,"given":"Viviane Zorzanelli","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6929","authenticated-orcid":false,"given":"Andr\u00e9","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-9434","authenticated-orcid":false,"given":"Fernando Henpin Yue","family":"Cesena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-2052","authenticated-orcid":false,"given":"Andrei Carvalho","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul Dias dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7206-9703","authenticated-orcid":false,"given":"Paulo Eduardo Ballv\u00e9","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-8327","authenticated-orcid":false,"given":"Henrique Tria","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-8717","authenticated-orcid":false,"given":"Renato Jorge","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-7317","authenticated-orcid":false,"given":"Andr\u00e9 Arpad","family":"Faludi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-7193","authenticated-orcid":false,"given":"Elaine dos Reis","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4598","authenticated-orcid":false,"given":"Francisco Antonio Helfenstein","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-356X","authenticated-orcid":false,"given":"Luiz S\u00e9rgio Fernandes de","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-0268","authenticated-orcid":false,"given":"Adriana","family":"Bertolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7939-8024","authenticated-orcid":false,"given":"Alo\u00edsio Marchi da","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-1820","authenticated-orcid":false,"given":"Ana Paula","family":"Marte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-6740","authenticated-orcid":false,"given":"Antonio Carlos Palandri","family":"Chagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-8456","authenticated-orcid":false,"given":"Bruno","family":"Caramelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-2577","authenticated-orcid":false,"given":"Carisi Anne","family":"Polanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-2544","authenticated-orcid":false,"given":"Carlos Eduardo dos Santos","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1224","authenticated-orcid":false,"suffix":"Junior","given":"Carlos Vicente","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-3737","authenticated-orcid":false,"given":"Daniel Branco de","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-0936","authenticated-orcid":false,"given":"Emilio Hideyuki","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8034-4529","authenticated-orcid":false,"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-0780","authenticated-orcid":false,"given":"Humberto Graner","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4056-9528","authenticated-orcid":false,"given":"Isabela de Carlos","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-0634","authenticated-orcid":false,"suffix":"Neto","given":"Jose Rocha","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1770-9306","authenticated-orcid":false,"given":"Kleisson Ant\u00f4nio Pontes","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0801-9729","authenticated-orcid":false,"given":"Marcelo Chiara","family":"Bertolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Heitor Vieira","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-2623","authenticated-orcid":false,"given":"Maria Cristina de Oliveira","family":"Izar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-9336","authenticated-orcid":false,"given":"Mauricio Alves","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-7078","authenticated-orcid":false,"given":"Natasha Slhessarenko Fraife","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-3537","authenticated-orcid":false,"given":"Pedro Gabriel Melo de Barros e","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Filho","given":"Pedro","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-4914","authenticated-orcid":false,"given":"Raul Cavalcante","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-8564","authenticated-orcid":false,"given":"Sergio Emanuel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6874-0657","authenticated-orcid":false,"given":"Valeria Arruda","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-8862","authenticated-orcid":false,"given":"Jose Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","reference":[{"issue":"10440","key":"key20251119150639_B1","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of Disease Scenarios for 204 Countries and Territories, 2022-2050: A Forecasting Analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators. Burden of Disease Scenarios for 204 Countries and Territories, 2022-2050: A Forecasting Analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204-56. doi: 10.1016\/S0140-6736(24)00685-8.","journal-title":"Lancet"},{"issue":"1","key":"key20251119150639_B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The Heart of the World","volume":"19","author":"Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The Heart of the World. Glob Heart. 2024;19(1):11. doi: 10.5334\/gh.1288.","journal-title":"Glob Heart"},{"issue":"7810","key":"key20251119150639_B3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the Global Epicentre of Non-Optimal Cholesterol","volume":"582","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2020","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the Global Epicentre of Non-Optimal Cholesterol. Nature. 2020;582(7810):73-7. doi: 10.1038\/s41586-020-2338-1.","journal-title":"Nature"},{"issue":"1","key":"key20251119150639_B4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL Cholesterol Goal Attainment and Its Relationship with Triglyceride Concentrations Among Diabetic Subjects with Cardiovascular Disease: A Nationwide Survey of 2674 Individuals in Hungary","volume":"241","author":"Mark","year":"2015","unstructured":"Mark L, Vallejo-Vaz AJ, Reiber I, Paragh G, Kondapally Seshasai SR, et al. Non-HDL Cholesterol Goal Attainment and Its Relationship with Triglyceride Concentrations Among Diabetic Subjects with Cardiovascular Disease: A Nationwide Survey of 2674 Individuals in Hungary. Atherosclerosis. 2015;241(1):62-8. doi: 10.1016\/j.atherosclerosis.2015.04.810.","journal-title":"Atherosclerosis"},{"issue":"1","key":"key20251119150639_B5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation Cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","unstructured":"Ray KK, Ference BA, S\u00e9verin T, Blom D, Nicholls SJ, Shiba MH, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022;17(1):75. doi: 10.5334\/gh.1154.","journal-title":"Glob Heart"},{"issue":"6","key":"key20251119150639_B6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cvr\/cvaf045","article-title":"Upfront Lipid-Lowering Combination Therapy in High Cardiovascular Risk Patients: A Route to Effective Atherosclerotic Cardiovascular Disease Prevention","volume":"121","author":"Banach","year":"2025","unstructured":"Banach M, Surma S, Guzik TJ, Penson PE, Blaha MJ, Pinto FJ, et al. Upfront Lipid-Lowering Combination Therapy in High Cardiovascular Risk Patients: A Route to Effective Atherosclerotic Cardiovascular Disease Prevention. Cardiovasc Res. 2025;121(6):851-9. doi: 10.1093\/cvr\/cvaf045.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"key20251119150639_B7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals with and without Atherosclerosis: Distinguishing between Particle Concentration, Type, and Content","volume":"7","author":"Marston","year":"2022","unstructured":"Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals with and without Atherosclerosis: Distinguishing between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250-6. doi: 10.1001\/jamacardio.2021.5083.","journal-title":"JAMA Cardiol"},{"key":"key20251119150639_B8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"290","author":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies","year":"2019","unstructured":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Atherosclerosis. 2019;290:140-205. doi: 10.1016\/j.atherosclerosis.2019.08.014.","journal-title":"Atherosclerosis"},{"key":"key20251119150639_B9","doi-asserted-by":"crossref","first-page":"n776","DOI":"10.1136\/bmj.n776","article-title":"Role of Coronary Artery Calcium Score in the Primary Prevention of Cardiovascular Disease","volume":"373","author":"Nasir","year":"2021","unstructured":"Nasir K, Cainzos-Achirica M. Role of Coronary Artery Calcium Score in the Primary Prevention of Cardiovascular Disease. BMJ. 2021;373:n776. doi: 10.1136\/bmj.n776.","journal-title":"BMJ"},{"issue":"25","key":"key20251119150639_B10","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20251119150639_B11","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240079","article-title":"Cardiovascular Statistics - Brazil 2023","volume":"121","author":"Oliveira","year":"2024","unstructured":"Oliveira GMM, Brant LCC, Polanczyk CA, Malta DC, Biolo A, Nascimento BR, et al. Cardiovascular Statistics - Brazil 2023. Arq Bras Cardiol. 2024;121(2):e20240079. doi: 10.36660\/abc.20240079.","journal-title":"Arq Bras Cardiol"},{"issue":"8","key":"key20251119150639_B12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jama.281.8.727","article-title":"Prevalence and Extent of Atherosclerosis in Adolescents and Young Adults: Implications for Prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study","volume":"281","author":"Strong","year":"1999","unstructured":"Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, et al. Prevalence and Extent of Atherosclerosis in Adolescents and Young Adults: Implications for Prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727-35. doi: 10.1001\/jama.281.8.727.","journal-title":"JAMA"},{"issue":"2","key":"key20251119150639_B13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2021.05.011","article-title":"Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7\/8","volume":"78","author":"Ibanez","year":"2021","unstructured":"Ibanez B, Fern\u00e1ndez-Ortiz A, Fern\u00e1ndez-Friera L, Garc\u00eda-Lunar I, Andr\u00e9s V, Fuster V. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7\/8. J Am Coll Cardiol. 2021;78(2):156-79. doi: 10.1016\/j.jacc.2021.05.011.","journal-title":"J Am Coll Cardiol"},{"key":"key20251119150639_B14","volume-title":"Global Health Data Exchange website [Internet]","author":"Global Burden of Disease Study 2019 (GBD 2019) Results","year":"2019","unstructured":"Global Burden of Disease Study 2019 (GBD 2019) Results. Global Health Data Exchange website [Internet]. Seattle: Institute for Health Metrics and Evaluation; 2019 [cited 2025 Aug 18]. Available from: http:\/\/ghdx.hea."},{"issue":"Suppl 02","key":"key20251119150639_B15","article-title":"Prevalence of Altered Total Cholesterol and Fractions in the Brazilian Adult Population: National Health Survey","volume":"22","author":"Malta","year":"2019","unstructured":"Malta DC, Szwarcwald CL, Machado \u00cdE, Pereira CA, Figueiredo AW, S\u00e1 ACMGN, et al. Prevalence of Altered Total Cholesterol and Fractions in the Brazilian Adult Population: National Health Survey. Rev Bras Epidemiol. 2019;22(Suppl 02):E190005.SUPL.2. doi: 10.1590\/1980-549720190005.supl.2.","journal-title":"Rev Bras Epidemiol"},{"issue":"spe1","key":"key20251119150639_B16","article-title":"Prevalence and Factors Associated with Self-Reported Diagnosis of High Cholesterol in the Brazilian Adult Population: National Health Survey 2019","volume":"31","author":"S\u00e1","year":"2022","unstructured":"S\u00e1 ACMGN, Gomes CS, Moreira AD, Velasquez-Melendez G, Malta DC. Prevalence and Factors Associated with Self-Reported Diagnosis of High Cholesterol in the Brazilian Adult Population: National Health Survey 2019. Epidemiol Serv Saude. 2022;31(spe1):e2021380. doi: 10.1590\/SS2237-9622202200002.especial.","journal-title":"Epidemiol Serv Saude"},{"key":"key20251119150639_B17","volume-title":"Vigitel Brasil 2016: Vigil\u00e2ncia de Fatores de Risco e Prote\u00e7\u00e3o para Doen\u00e7as Cr\u00f4nicas por Inqu\u00e9rito Telef\u00f4nico: Estimativas sobre Frequ\u00eancia e Distribui\u00e7\u00e3o Sociodemogr\u00e1fica de Fatores de Risco e Prote\u00e7\u00e3o para Doen\u00e7as Cr\u00f4nicas nas Capitais dos 26 Estados Brasileiros e no Distrito Federal em 2016","author":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia de Doen\u00e7as e Agravos n\u00e3o Transmiss\u00edveis e Promo\u00e7\u00e3o da Sa\u00fade","year":"2016","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia de Doen\u00e7as e Agravos n\u00e3o Transmiss\u00edveis e Promo\u00e7\u00e3o da Sa\u00fade. Vigitel Brasil 2016: Vigil\u00e2ncia de Fatores de Risco e Prote\u00e7\u00e3o para Doen\u00e7as Cr\u00f4nicas por Inqu\u00e9rito Telef\u00f4nico: Estimativas sobre Frequ\u00eancia e Distribui\u00e7\u00e3o Sociodemogr\u00e1fica de Fatores de Risco e Prote\u00e7\u00e3o para Doen\u00e7as Cr\u00f4nicas nas Capitais dos 26 Estados Brasileiros e no Distrito Federal em 2016. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2016."},{"issue":"1","key":"key20251119150639_B18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ije\/dyu027","article-title":"Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"44","author":"Schmidt","year":"2015","unstructured":"Schmidt MI, Duncan BB, Mill JG, Lotufo PA, Chor D, Barreto SM, et al. Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil). Int J Epidemiol. 2015;44(1):68-75. doi: 10.1093\/ije\/dyu027.","journal-title":"Int J Epidemiol"},{"key":"key20251119150639_B19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2018.08.021","article-title":"Familial Hypercholesterolemia Prevalence in an Admixed Racial Society: Sex and Race Matter. The ELSA-Brasil","volume":"277","author":"Harada","year":"2018","unstructured":"Harada PH, Miname MH, Bense\u00f1or IM, Santos RD, Lotufo PA. Familial Hypercholesterolemia Prevalence in an Admixed Racial Society: Sex and Race Matter. The ELSA-Brasil. Atherosclerosis. 2018;277:273-7. doi: 10.1016\/j.atherosclerosis.2018.08.021.","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"key20251119150639_B20","first-page":"10s","article-title":"ERICA: Prevalence of Dyslipidemia in Brazilian Adolescents","volume":"50","author":"Faria","year":"2016","unstructured":"Faria JR Neto, Bento VF, Baena CP, Olandoski M, Gon\u00e7alves LG, Abreu GA, et al. ERICA: Prevalence of Dyslipidemia in Brazilian Adolescents. Rev Saude Publica. 2016;50(Suppl 1):10s. doi: 10.1590\/S01518-8787.2016050006723.","journal-title":"Rev Saude Publica"},{"issue":"3","key":"key20251119150639_B21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2015.12.029","article-title":"Prevalence, Awareness, Treatment, and Control of High Low-Density Lipoprotein Cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"10","author":"Lotufo","year":"2016","unstructured":"Lotufo PA, Santos RD, Figueiredo RM, Pereira AC, Mill JG, Alvim SM, et al. Prevalence, Awareness, Treatment, and Control of High Low-Density Lipoprotein Cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Lipidol. 2016;10(3):568-76. doi: 10.1016\/j.jacl.2015.12.029.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"key20251119150639_B22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","unstructured":"Waters DD, Brotons C, Chiang CW, Ferri\u00e8res J, Foody J, Jukema JW, et al. Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein cholesterol goals. Circulation. 2009;120(1):28-34. doi: 10.1161\/CIRCULATIONAHA.108.838466.","journal-title":"Circulation"},{"issue":"11","key":"key20251119150639_B23","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240116i","article-title":"Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil","volume":"121","author":"Santos","year":"2024","unstructured":"Santos RD, Kashiwagi NM, Cesena FY, Assis SRL, Nieri J, Minanni CA, et al. Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil. Arq Bras Cardiol. 2024;121(11):e20240116. doi: 10.36660\/abc.20240116.","journal-title":"Arq Bras Cardiol"},{"key":"key20251119150639_B24","author":"Barros e Silva","year":"2025","unstructured":"Barros e Silva PGM, Rached FH, Miname MH, Tramujas L, Peron RAN, Nascimento CT, et al. Optimal Implementation of the 2025 Brazilian Guidelines of Dyslipidaemia in Patients with Atherothrombotic Disease: A Simulation Based on the NEAT study. 2025. Ahead of print.","journal-title":"Optimal Implementation of the 2025 Brazilian Guidelines of Dyslipidaemia in Patients with Atherothrombotic Disease: A Simulation Based on the NEAT study"},{"issue":"1","key":"key20251119150639_B25","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1038\/s41598-024-54516-9","article-title":"Primary Results of the Brazilian Registry of Atherothrombotic Disease (NEAT)","volume":"14","author":"Barros e Silva","year":"2024","unstructured":"Barros e Silva PGM, Nascimento CT, Pedrosa RP, Nakazone MA, Nascimento MU, Melo LA, et al. Primary Results of the Brazilian Registry of Atherothrombotic Disease (NEAT). Sci Rep. 2024;14(1):4222. doi: 10.1038\/s41598-024-54516-9.","journal-title":"Sci Rep"},{"key":"key20251119150639_B26","first-page":"100534","article-title":"Assessing Statins Use in a Real-World Primary Care Digital Strategy: A Cross-Sectional Analysis of a Population-Wide Digital Health Approach","volume":"23","author":"Machline-Carrion","year":"2023","unstructured":"Machline-Carrion MJ, Girotto AN, Nieri J, Pereira PM, Monfardini F, Forestiero F, et al. Assessing Statins Use in a Real-World Primary Care Digital Strategy: A Cross-Sectional Analysis of a Population-Wide Digital Health Approach. Lancet Reg Health Am. 2023;23:100534. doi: 10.1016\/j.lana.2023.100534.","journal-title":"Lancet Reg Health Am"},{"issue":"11","key":"key20251119150639_B27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI Study","volume":"28","author":"Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI Study. Eur J Prev Cardiol. 2021;28(11):1279-89. doi: 10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"key20251119150639_B28","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients with Atherosclerotic Cardiovascular Disease in the US","volume":"6","author":"Cannon","year":"2021","unstructured":"Cannon CP, Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients with Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6(9):1060-8. doi: 10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"issue":"9798","key":"key20251119150639_B29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of Secondary Prevention Drugs for Cardiovascular Disease in the Community in High-Income, Middle-Income, and Low-Income Countries (the PURE Study): A Prospective Epidemiological Survey","volume":"378","author":"Yusuf","year":"2011","unstructured":"Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of Secondary Prevention Drugs for Cardiovascular Disease in the Community in High-Income, Middle-Income, and Low-Income Countries (the PURE Study): A Prospective Epidemiological Survey. Lancet. 2011;378(9798):1231-43. doi: 10.1016\/S0140-6736(11)61215-4.","journal-title":"Lancet"},{"issue":"3","key":"key20251119150639_B30","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S2214-109X(21)00551-9","article-title":"Use of Statins for the Prevention of Cardiovascular Disease in 41 Low-Income and Middle-Income Countries: A Cross-Sectional Study of Nationally Representative, Individual-Level Data","volume":"10","author":"Marcus","year":"2022","unstructured":"Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, et al. Use of Statins for the Prevention of Cardiovascular Disease in 41 Low-Income and Middle-Income Countries: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. Lancet Glob Health. 2022;10(3):e369-e379. doi: 10.1016\/S2214-109X(21)00551-9.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"key20251119150639_B31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/03007995.2018.1451312","article-title":"Statin use in Brazil: Findings and Implications","volume":"34","author":"Nascimento","year":"2018","unstructured":"Nascimento RCRM, Guerra AA Jr, Alvares J, Gomes IC, Godman B, Bennie M, et al. Statin use in Brazil: Findings and Implications. Curr Med Res Opin. 2018;34(10):1809-17. doi: 10.1080\/03007995.2018.1451312.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"key20251119150639_B32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.36660\/abc.20190513","article-title":"Statins Prescriptions and Lipid Levels in a Tertiary Public Hospital","volume":"116","author":"Schmidt","year":"2021","unstructured":"Schmidt A, Moreira HT, Volpe GJ, Foschini VB, Lascala TF, Romano MMD, et al. Statins Prescriptions and Lipid Levels in a Tertiary Public Hospital. Arq Bras Cardiol. 2021;116(4):736-41. doi: 10.36660\/abc.20190513.","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"key20251119150639_B33","doi-asserted-by":"crossref","first-page":"742","DOI":"10.36660\/abc.20210089","article-title":"Statin Use and Hypercholesterolemia: Are the Current Guidelines\u2019 Recommendations Being Followed?","volume":"116","author":"Alves","year":"2021","unstructured":"Alves RJ. Statin Use and Hypercholesterolemia: Are the Current Guidelines\u2019 Recommendations Being Followed? Arq Bras Cardiol. 2021;116(4):742-3. doi: 10.36660\/abc.20210089.","journal-title":"Arq Bras Cardiol"},{"issue":"3","key":"key20251119150639_B34","article-title":"Preanalytical Errors in Clinical Laboratory Testing at a Glance: Source and Control Measures","volume":"16","author":"Nordin","year":"2024","unstructured":"Nordin N, Ab Rahim SN, Wan Omar WFA, Zulkarnain S, Sinha S, Kumar S, et al. Preanalytical Errors in Clinical Laboratory Testing at a Glance: Source and Control Measures. Cureus. 2024;16(3):e57243. doi: 10.7759\/cureus.57243.","journal-title":"Cureus"},{"issue":"5","key":"key20251119150639_B35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/jalm\/jfae057","article-title":"ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins","volume":"9","author":"Cao","year":"2024","unstructured":"Cao J, Donato L, El-Khoury JM, Goldberg A, Meeusen JW, Remaley AT. ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2024;9(5):1040-56. doi: 10.1093\/jalm\/jfae057.","journal-title":"J Appl Lab Med"},{"issue":"17","key":"key20251119150639_B36","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1073\/pnas.84.17.6259","article-title":"Individual Variation in Serum Cholesterol Levels","volume":"84","author":"Hegsted","year":"1987","unstructured":"Hegsted DM, Nicolosi RJ. Individual Variation in Serum Cholesterol Levels. Proc Natl Acad Sci U S A. 1987;84(17):6259-61. doi: 10.1073\/pnas.84.17.6259.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2 Supl 1","key":"key20251119150639_B37","first-page":"1","article-title":"Atualiza\u00e7\u00e3o da Diretriz Brasileira de Dislipidemias e Preven\u00e7\u00e3o da Aterosclerose \u2013 2017","volume":"109","author":"Faludi","year":"2017","unstructured":"Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A Neto, et al. Atualiza\u00e7\u00e3o da Diretriz Brasileira de Dislipidemias e Preven\u00e7\u00e3o da Aterosclerose \u2013 2017. Arq Bras Cardiol. 2017;109(2 Supl 1):1-76. doi: 10.5935\/abc.20170121.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"key20251119150639_B38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5334\/gh.1214","article-title":"Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients","volume":"18","author":"Samuel","year":"2023","unstructured":"Samuel C, Park J, Sajja A, Michos ED, Blumenthal RS, Jones SR, et al. Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients. Glob Heart. 2023;18(1):36. doi: 10.5334\/gh.1214.","journal-title":"Glob Heart"},{"issue":"3","key":"key20251119150639_B39","first-page":"195","article-title":"Positioning about the Flexibility of Fasting for Lipid Profiling","volume":"108","author":"Scartezini","year":"2017","unstructured":"Scartezini M, Ferreira CEDS, Izar MCO, Bertoluci M, Vencio S, Campana GA, et al. Positioning about the Flexibility of Fasting for Lipid Profiling. Arq Bras Cardiol. 2017;108(3):195-7. doi: 10.5935\/abc.20170039.","journal-title":"Arq Bras Cardiol"},{"issue":"167","key":"key20251119150639_B40","doi-asserted-by":"crossref","DOI":"10.3791\/61790","article-title":"Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation","author":"Niimi","year":"2021","unstructured":"Niimi M, Yan H, Chen Y, Wang Y, Fan J. Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation. J Vis Exp. 2021;(167). doi: 10.3791\/61790.","journal-title":"J Vis Exp"},{"issue":"1","key":"key20251119150639_B41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2015.08.042","article-title":"A Comparative Study of four Independent Methods to Measure LDL Particle Concentration","volume":"243","author":"Hopkins","year":"2015","unstructured":"Hopkins PN, Pottala JV, Nanjee MN. A Comparative Study of four Independent Methods to Measure LDL Particle Concentration. Atherosclerosis. 2015;243(1):99-106. doi: 10.1016\/j.atherosclerosis.2015.08.042.","journal-title":"Atherosclerosis"},{"issue":"16","key":"key20251119150639_B42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clinbiochem.2014.07.015","article-title":"NMR Measurement of LDL Particle Number using the Vantera Clinical Analyzer","volume":"47","author":"Matyus","year":"2014","unstructured":"Matyus SP, Braun PJ, Wolak-Dinsmore J, Jeyarajah EJ, Shalaurova I, Xu Y, et al. NMR Measurement of LDL Particle Number using the Vantera Clinical Analyzer. Clin Biochem. 2014;47(16):203-10. doi: 10.1016\/j.clinbiochem.2014.07.015.","journal-title":"Clin Biochem"},{"issue":"5","key":"key20251119150639_B43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations a Scientific Statement from the National Lipid Association Writing Group","volume":"15","author":"Wilson","year":"2021","unstructured":"Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH, et al. Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations a Scientific Statement from the National Lipid Association Writing Group. J Clin Lipidol. 2021;15(5):629-48. doi: 10.1016\/j.jacl.2021.09.046.","journal-title":"J Clin Lipidol"},{"issue":"9","key":"key20251119150639_B44","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.9723","article-title":"Identification of Multiple Plasma Lipids as Diagnostic Biomarkers of Hypercholesterolemia and the Underlying Mechanisms Based on Pseudo-Targeted Lipidomics","volume":"38","author":"Zhao","year":"2024","unstructured":"Zhao R, Tang Y, Cao W, Zhao L, Wu Z, Chen X, et al. Identification of Multiple Plasma Lipids as Diagnostic Biomarkers of Hypercholesterolemia and the Underlying Mechanisms Based on Pseudo-Targeted Lipidomics. Rapid Commun Mass Spectrom. 2024;38(9):e9723. doi: 10.1002\/rcm.9723.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"key20251119150639_B45","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/acs.jproteome.2c00682","article-title":"Comprehensive Lipidomic Workflow for Multicohort Population Phenotyping Using Stable Isotope Dilution Targeted Liquid Chromatography-Mass Spectromery","volume":"22","author":"Ryan","year":"2023","unstructured":"Ryan MJ, Grant-St James A, Lawler NG, Fear MW, Raby E, Wood FM, et al. Comprehensive Lipidomic Workflow for Multicohort Population Phenotyping Using Stable Isotope Dilution Targeted Liquid Chromatography-Mass Spectromery. J Proteome Res. 2023;22(5):1419-33. doi: 10.1021\/acs.jproteome.2c00682.","journal-title":"J Proteome Res"},{"issue":"5","key":"key20251119150639_B46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/14789450.2015.1078731","article-title":"Mass Spectrometry Meets the Challenge of Understanding the Complexity of the Lipoproteome: Recent Findings Regarding Proteins Involved in Dyslipidemia and Cardiovascular Disease","volume":"12","author":"Singh","year":"2015","unstructured":"Singh SA, Miyosawa K, Aikawa M. Mass Spectrometry Meets the Challenge of Understanding the Complexity of the Lipoproteome: Recent Findings Regarding Proteins Involved in Dyslipidemia and Cardiovascular Disease. Expert Rev Proteomics. 2015;12(5):519-32. doi: 10.1586\/14789450.2015.1078731.","journal-title":"Expert Rev Proteomics"},{"key":"key20251119150639_B47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cca.2015.08.027","article-title":"Impact of Automation on Mass Spectrometry","volume":"450","author":"Zhang","year":"2015","unstructured":"Zhang YV, Rockwood A. Impact of Automation on Mass Spectrometry. Clin Chim Acta. 2015;450:298-303. doi: 10.1016\/j.cca.2015.08.027.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"key20251119150639_B48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/jbcpp-2025-0029","article-title":"Point-of-Care Testing: Revolutionizing Clinical Biochemistry Using Decentralized Diagnostics","volume":"36","author":"Shaikh","year":"2025","unstructured":"Shaikh S, Panchbudhe SA, Shivkar RR, Banerjee A, Deshmukh P, Kadam CY. Point-of-Care Testing: Revolutionizing Clinical Biochemistry Using Decentralized Diagnostics. J Basic Clin Physiol Pharmacol. 2025;36(2):113-28. doi: 10.1515\/jbcpp-2025-0029.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"1","key":"key20251119150639_B49","first-page":"1","article-title":"Point-of-Care Testing: General Aspects","volume":"64","author":"Ferreira","year":"2018","unstructured":"Ferreira CES, Guerra JCC, Slhessarenko N, Scartezini M, Franca CN, Colombini MP, et al. Point-of-Care Testing: General Aspects. Clin Lab. 2018;64(1):1-9. doi: 10.7754\/Clin.Lab.2017.170730.","journal-title":"Clin Lab"},{"key":"key20251119150639_B50","volume-title":"Resolu\u00e7\u00e3o ANVISA n\u00ba 978, de 6 de junho de 2025","author":"Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2025","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o ANVISA n\u00ba 978, de 6 de junho de 2025. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, 10 jun 2025."},{"key":"key20251119150639_B51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cca.2015.04.036","article-title":"Clinical Correlation between a Point-of-Care Testing System and Laboratory Automation for Lipid Profile","volume":"446","author":"Ferreira","year":"2015","unstructured":"Ferreira CE, Fran\u00e7a CN, Correr CJ, Zucker ML, Andriolo A, Scartezini M. Clinical Correlation between a Point-of-Care Testing System and Laboratory Automation for Lipid Profile. Clin Chim Acta. 2015;446:263-6. doi: 10.1016\/j.cca.2015.04.036.","journal-title":"Clin Chim Acta"},{"issue":"596","key":"key20251119150639_B52","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.3399\/bjgp12X630241","article-title":"Point-of-Care Testing for the Analysis of Lipid Panels: Primary Care Diagnostic Technology Update","volume":"62","author":"Pl\u00fcddemann","year":"2012","unstructured":"Pl\u00fcddemann A, Thompson M, Price CP, Wolstenholme J, Heneghan C. Point-of-Care Testing for the Analysis of Lipid Panels: Primary Care Diagnostic Technology Update. Br J Gen Pract. 2012;62(596):e224-6. doi: 10.3399\/bjgp12X630241.","journal-title":"Br J Gen Pract"},{"issue":"19","key":"key20251119150639_B53","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile","volume":"310","author":"Martin","year":"2013","unstructured":"Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile. JAMA. 2013;310(19):2061-8. doi: 10.1001\/jama.2013.280532.","journal-title":"JAMA"},{"key":"key20251119150639_B54","doi-asserted-by":"crossref","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-Cholesterol in Dyslipidemia: Review of the State-of-the-Art Literature and Outlook","volume":"383","author":"Raja","year":"2023","unstructured":"Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, et al. Non-HDL-Cholesterol in Dyslipidemia: Review of the State-of-the-Art Literature and Outlook. Atherosclerosis. 2023;383:117312. doi: 10.1016\/j.atherosclerosis.2023.117312.","journal-title":"Atherosclerosis"},{"issue":"1","key":"key20251119150639_B55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J. 2020;41(1):111-88. doi: 10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"20","key":"key20251119150639_B56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk","volume":"11","author":"Glavinovic","year":"2022","unstructured":"Glavinovic T, Thanassoulis G, Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Assoc. 2022;11(20):e025858. doi: 10.1161\/JAHA.122.025858.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"key20251119150639_B57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease","volume":"140","author":"Welsh","year":"2019","unstructured":"Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation. 2019;140(7):542-52. doi: 10.1161\/CIRCULATIONAHA.119.041149.","journal-title":"Circulation"},{"issue":"100","key":"key20251119150639_B58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta191000","article-title":"Optimal Strategies for Monitoring Lipid Levels in Patients at Risk or with Cardiovascular Disease: A Systematic Review with Statistical and Cost-Effectiveness Modelling","volume":"19","author":"Perera","year":"2015","unstructured":"Perera R, McFadden E, McLellan J, Lung T, Clarke P, P\u00e9rez T, et al. Optimal Strategies for Monitoring Lipid Levels in Patients at Risk or with Cardiovascular Disease: A Systematic Review with Statistical and Cost-Effectiveness Modelling. Health Technol Assess. 2015;19(100):1-401, vii-viii. doi: 10.3310\/hta191000.","journal-title":"Health Technol Assess"},{"issue":"6","key":"key20251119150639_B59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age","volume":"113","author":"Lloyd-Jones","year":"2006","unstructured":"Lloyd-Jones DM, Leip EP, Larson MG, D\u2019Agostino RB, Beiser A, Wilson PW, et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. 2006;113(6):791-8. doi: 10.1161\/CIRCULATIONAHA.105.548206.","journal-title":"Circulation"},{"issue":"7","key":"key20251119150639_B60","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","unstructured":"Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem. 2018;64(7):1006-33. doi: 10.1373\/clinchem.2018.287037.","journal-title":"Clin Chem"},{"issue":"5","key":"key20251119150639_B61","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of Lipoprotein(a) Molar Concentrations and Mass According to Lipoprotein(a) Thresholds and Apolipoprotein(a) Isoform Size","volume":"12","author":"Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of Lipoprotein(a) Molar Concentrations and Mass According to Lipoprotein(a) Thresholds and Apolipoprotein(a) Isoform Size. J Clin Lipidol. 2018;12(5):1313-23. doi: 10.1016\/j.jacl.2018.07.003.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"key20251119150639_B62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","unstructured":"Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125(2):241-9. doi: 10.1161\/CIRCULATIONAHA.111.045120.","journal-title":"Circulation"},{"key":"key20251119150639_B63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) Levels from Childhood to Adulthood: Data in Nearly 3,000 Children who Visited a Pediatric Lipid Clinic","volume":"349","author":"Boer","year":"2022","unstructured":"Boer LM, Hof MH, Wiegman A, Stroobants AK, Kastelein JJP, Hutten BA. Lipoprotein(a) Levels from Childhood to Adulthood: Data in Nearly 3,000 Children who Visited a Pediatric Lipid Clinic. Atherosclerosis. 2022;349:227-32. doi: 10.1016\/j.atherosclerosis.2022.03.004.","journal-title":"Atherosclerosis"},{"issue":"1","key":"key20251119150639_B64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights from a Large National Biobank","volume":"41","author":"Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights from a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465-74. doi: 10.1161\/ATVBAHA.120.315291.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"key20251119150639_B65","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease","volume":"80","author":"Hedegaard","year":"2022","unstructured":"Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2022;80(21):1998-2010. doi: 10.1016\/j.jacc.2022.09.021.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20251119150639_B66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study","volume":"40","author":"Madsen","year":"2020","unstructured":"Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2020;40(1):255-66. doi: 10.1161\/ATVBAHA.119.312951.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20251119150639_B67","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.ajpc.2024.100641","article-title":"Lipoprotein(a): Emerging Insights and Therapeutics","volume":"18","author":"Kaur","year":"2024","unstructured":"Kaur G, Abdelrahman K, Berman AN, Biery DW, Shiyovich A, Huck D, et al. Lipoprotein(a): Emerging Insights and Therapeutics. Am J Prev Cardiol. 2024;18:100641. doi: 10.1016\/j.ajpc.2024.100641.","journal-title":"Am J Prev Cardiol"},{"issue":"22","key":"key20251119150639_B68","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia","volume":"67","author":"Khera","year":"2016","unstructured":"Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-89. doi: 10.1016\/j.jacc.2016.03.520.","journal-title":"J Am Coll Cardiol"},{"issue":"6319","key":"key20251119150639_B69","doi-asserted-by":"crossref","first-page":"aaf7000","DOI":"10.1126\/science.aaf7000","article-title":"Genetic Identification of Familial Hypercholesterolemia Within a Single U.S. health Care System","volume":"354","author":"Abul-Husn","year":"2016","unstructured":"Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga-Jauregui C, et al. Genetic Identification of Familial Hypercholesterolemia Within a Single U.S. health Care System. Science. 2016;354(6319):aaf7000. doi: 10.126\/science.aaf7000.","journal-title":"Science"},{"issue":"6","key":"key20251119150639_B70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-0004.2004.00320.x","article-title":"Cascade Genetic Screening for Familial Hypercholesterolemia","volume":"66","author":"Leren","year":"2004","unstructured":"Leren TP. Cascade Genetic Screening for Familial Hypercholesterolemia. Clin Genet. 2004;66(6):483-7. doi: 10.1111\/j.1399-0004.2004.00320.x.","journal-title":"Clin Genet"},{"issue":"9251","key":"key20251119150639_B71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of First 5 Years of Screening for Familial Hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","unstructured":"Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of First 5 Years of Screening for Familial Hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-8. doi: 10.1016\/S0140-6736(00)03587-X.","journal-title":"Lancet"},{"issue":"1","key":"key20251119150639_B72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archinte.163.1.65","article-title":"Long-Term Compliance with Lipid-Lowering Medication after Genetic Screening for Familial Hypercholesterolemia","volume":"163","author":"Umans-Eckenhausen","year":"2003","unstructured":"Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Long-Term Compliance with Lipid-Lowering Medication after Genetic Screening for Familial Hypercholesterolemia. Arch Intern Med. 2003;163(1):65-8. doi: 10.1001\/archinte.163.1.65.","journal-title":"Arch Intern Med"},{"issue":"Pt 1","key":"key20251119150639_B73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1258\/acb.2008.008094","article-title":"Family Tracing to Identify Patients with Familial Hypercholesterolaemia: The Second Audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project","volume":"46","author":"Hadfield","year":"2009","unstructured":"Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, et al. Family Tracing to Identify Patients with Familial Hypercholesterolaemia: The Second Audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem. 2009;46(Pt 1):24-32. doi: 10.1258\/acb.2008.008094.","journal-title":"Ann Clin Biochem"},{"issue":"14","key":"key20251119150639_B74","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","article-title":"Probabilistic Cost-Effectiveness Analysis of Cascade Screening for Familial Hypercholesterolaemia Using Alternative Diagnostic and Identification Strategies","volume":"97","author":"Nherera","year":"2011","unstructured":"Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic Cost-Effectiveness Analysis of Cascade Screening for Familial Hypercholesterolaemia Using Alternative Diagnostic and Identification Strategies. Heart. 2011;97(14):1175-81. doi: 10.1136\/hrt.2010.213975.","journal-title":"Heart"},{"issue":"7349","key":"key20251119150639_B75","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/bmj.324.7349.1303","article-title":"Cost Effectiveness Analysis of Different Approaches of Screening for Familial Hypercholesterolaemia","volume":"324","author":"Marks","year":"2002","unstructured":"Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost Effectiveness Analysis of Different Approaches of Screening for Familial Hypercholesterolaemia. BMJ. 2002;324(7349):1303. doi: 10.1136\/bmj.324.7349.1303.","journal-title":"BMJ"},{"issue":"29","key":"key20251119150639_B76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4290","article-title":"Screening for Hypercholesterolaemia versus Case Finding for Familial Hypercholesterolaemia: A Systematic Review and Cost-Effectiveness Analysis","volume":"4","author":"Marks","year":"2000","unstructured":"Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for Hypercholesterolaemia versus Case Finding for Familial Hypercholesterolaemia: A Systematic Review and Cost-Effectiveness Analysis. Health Technol Assess. 2000;4(29):1-123.","journal-title":"Health Technol Assess"},{"issue":"23","key":"key20251119150639_B77","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","article-title":"Cost Effectiveness of Cascade Testing for Familial Hypercholesterolaemia, Based on Data from Familial Hypercholesterolaemia Services in the UK","volume":"38","author":"Kerr","year":"2017","unstructured":"Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, et al. Cost Effectiveness of Cascade Testing for Familial Hypercholesterolaemia, Based on Data from Familial Hypercholesterolaemia Services in the UK. Eur Heart J. 2017;38(23):1832-9. doi: 10.1093\/eurheartj\/ehx111.","journal-title":"Eur Heart J"},{"issue":"4","key":"key20251119150639_B78","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","article-title":"Cascade Screening Based on Genetic Testing is Cost-Effective: Evidence for the Implementation of Models of Care for Familial Hypercholeserolemia","volume":"8","author":"Ademi","year":"2014","unstructured":"Ademi Z, Watts GF, Pang J, Sijbrands EJ, van Bockxmeer FM, O\u2019Leary P, et al. Cascade Screening Based on Genetic Testing is Cost-Effective: Evidence for the Implementation of Models of Care for Familial Hypercholeserolemia. J Clin Lipidol. 2014;8(4):390-400. doi: 10.1016\/j.jacl.2014.05.008.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"key20251119150639_B79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-822992","article-title":"Cost-Effectiveness Analysis of the Genetic Screening Program for Familial Hypercholesterolemia in the Netherlands","volume":"4","author":"Wonderling","year":"2004","unstructured":"Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-Effectiveness Analysis of the Genetic Screening Program for Familial Hypercholesterolemia in the Netherlands. Semin Vasc Med. 2004;4(1):97-104. doi: 10.1055\/s-2004-822992.","journal-title":"Semin Vasc Med"},{"issue":"1","key":"key20251119150639_B80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","article-title":"Cost-Effectiveness of a Cascade Screening Program for the Early Detection of Familial Hypercholesterolemia","volume":"11","author":"L\u00e1zaro","year":"2017","unstructured":"L\u00e1zaro P, de Isla LP, Watts GF, Alonso R, Norman R, Mu\u00f1iz O, et al. Cost-Effectiveness of a Cascade Screening Program for the Early Detection of Familial Hypercholesterolemia. J Clin Lipidol. 2017;11(1):260-71. doi: 10.1016\/j.jacl.201.01.002.","journal-title":"J Clin Lipidol"},{"issue":"7275","key":"key20251119150639_B81","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/bmj.321.7275.1497","article-title":"Outcome of Case Finding Among Relatives of Patients with Known Heterozygous Familial Hypercholesterolaemia","volume":"321","author":"Bhatnagar","year":"2000","unstructured":"Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of Case Finding Among Relatives of Patients with Known Heterozygous Familial Hypercholesterolaemia. BMJ. 2000;321(7275):1497-500. doi: 10.1136\/bmj.321.7275.1497.","journal-title":"BMJ"},{"issue":"3","key":"key20251119150639_B82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","unstructured":"Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171(3):309-25. doi: 10.1016\/j.ijcard.2013.11.025.","journal-title":"Int J Cardiol"},{"issue":"45","key":"key20251119150639_B83","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial Hypercholesterolaemia is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial Hypercholesterolaemia is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi: 10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"issue":"25","key":"key20251119150639_B84","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: New Treatments and Clinical Guidance","volume":"44","author":"Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: New Treatments and Clinical Guidance. Eur Heart J. 2023;44(25):2277-91. doi: 10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"issue":"6","key":"key20251119150639_B85","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jacl.2016.09.003","article-title":"Double-Heterozygous Autosomal Dominant Hypercholesterolemia: Clinical Characterization of an Underreported Disease","volume":"10","author":"Sjouke","year":"2016","unstructured":"Sjouke B, Defesche JC, Hartgers ML, Wiegman A, van Lennep JER, Kastelein JJ, et al. Double-Heterozygous Autosomal Dominant Hypercholesterolemia: Clinical Characterization of an Underreported Disease. J Clin Lipiol. 2016;10(6):1462-9. doi: 10.1016\/j.jacl.2016.09.003.","journal-title":"J Clin Lipiol"},{"issue":"1","key":"key20251119150639_B86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajhg.2015.05.022","article-title":"Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents","volume":"97","author":"Botkin","year":"2015","unstructured":"Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA, et al. Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Hum Genet. 2015;97(1):6-21. doi: 10.1016\/j.ajhg.2015.05.022.","journal-title":"Am J Hum Genet"},{"issue":"36","key":"key20251119150639_B87","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment","volume":"36","author":"Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment. Eur Heart J. 2015;36(36):2425-37. doi: 10.1093\/eurheartj\/ehv157.","journal-title":"Eur Heart J"},{"issue":"4","key":"key20251119150639_B88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacc.2015.11.021","article-title":"Statin Initiation during Childhood in Patients with Familial Hypercholesterolemia: Consequences for Cardiovascular Risk","volume":"67","author":"Braamskamp","year":"2016","unstructured":"Braamskamp MJAM, Kastelein JJP, Kusters DM, Hutten BA, Wiegman A. Statin Initiation during Childhood in Patients with Familial Hypercholesterolemia: Consequences for Cardiovascular Risk. J Am Coll Cardiol. 2016;67(4):455-6. doi: 10.1016\/j.jacc.2015.11.021.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20251119150639_B89","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","unstructured":"Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(6):662-80. doi: 10.1016\/j.jac.2018.05.044.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20251119150639_B90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacl.2018.02.018","article-title":"Roundtable Discussion: Familial Chylomicronemia Syndrome: Diagnosis and Management","volume":"12","author":"Brown","year":"2018","unstructured":"Brown WV, Goldberg I, Duell B, Gaudet D. Roundtable Discussion: Familial Chylomicronemia Syndrome: Diagnosis and Management. J Clin Lipidol. 2018;12(2):254-63. doi: 10.1016\/j.jacl.2018.02.018.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"key20251119150639_B91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical Review on Triglycerides","volume":"41","author":"Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical Review on Triglycerides. Eur Heart J. 2020;41(1):99-109c. doi: 10.1093\/eurheartj\/ehz785.","journal-title":"Eur Heart J"},{"key":"key20251119150639_B92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: Differences between Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia","volume":"283","author":"Paquette","year":"2019","unstructured":"Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: Differences between Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia. Atherosclerosis. 2019;283:137-42. doi: 10.1016\/j.atherosclerosis.2018.12.019.","journal-title":"Atherosclerosis"},{"key":"key20251119150639_B93","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of Hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","unstructured":"Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol. 2020;11:455. doi: 10.3389\/fendo.2020.00455.","journal-title":"Front Endocrinol"},{"issue":"9","key":"key20251119150639_B94","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The Chylomicronemia Syndrome is Most Often Multifactorial: A Narrative Review of Causes and Treatment","volume":"170","author":"Chait","year":"2019","unstructured":"Chait A, Eckel RH. The Chylomicronemia Syndrome is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Ann Intern Med. 2019;170(9):626-34. doi: 10.7326\/M19-0203.","journal-title":"Ann Intern Med"},{"issue":"4","key":"key20251119150639_B95","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited Lipodystrophies and Hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","unstructured":"Simha V, Garg A. Inherited Lipodystrophies and Hypertriglyceridemia. Curr Opin Lipidol. 2009;20(4):300-8. doi: 10.1097\/MOL.0b013e32832d4a33.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"key20251119150639_B96","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial Chylomicronemia Syndrome: An Under-Recognized Cause of Severe Hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","unstructured":"Baass A, Paquette M, Bernard S, Hegele RA. Familial Chylomicronemia Syndrome: An Under-Recognized Cause of Severe Hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. doi: 10.1111\/joim.13016.","journal-title":"J Intern Med"},{"issue":"4","key":"key20251119150639_B97","article-title":"Brazilian Position Statement for Familial Chylomicronemia Syndrome - 2023","volume":"120","author":"Izar","year":"2023","unstructured":"Izar MCO, Santos RDD Filho, Assad MHV, Chagas ACP, Toledo AO Jr, Nogueira ACC, et al. Brazilian Position Statement for Familial Chylomicronemia Syndrome - 2023. Arq Bras Cardiol. 2023;120(4):e20230203. doi: 10.36660\/abc.20230203.","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"key20251119150639_B98","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacl.2021.10.004","article-title":"Challenges in Familial Chylomicronemia Syndrome Diagnosis and Management Across Latin American Countries: An Expert Panel Discussion","volume":"15","author":"Santos","year":"2021","unstructured":"Santos RD, Lorenzatti A, Corral P, Nogueira JP, Cafferata AM, Aimone D, et al. Challenges in Familial Chylomicronemia Syndrome Diagnosis and Management Across Latin American Countries: An Expert Panel Discussion. J Clin Lipidol. 2021;15(5):620-4. doi: 10.1016\/j.jacl.2021.10.004.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"key20251119150639_B99","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","article-title":"Hypertriglyceridemia and Acute Pancreatitis","volume":"173","author":"Murphy","year":"2013","unstructured":"Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and Acute Pancreatitis. JAMA Intern Med. 2013;173(2):162-4. doi: 10.1001\/2013.jamainternmed.477.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"key20251119150639_B100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","article-title":"Familial Chylomicronemia Syndrome: A Rare but Devastating Autosomal Recessive Disorder Characterized by Refractory Hypertriglyceridemia and Recurrent Pancreatitis","volume":"30","author":"Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS. Familial Chylomicronemia Syndrome: A Rare but Devastating Autosomal Recessive Disorder Characterized by Refractory Hypertriglyceridemia and Recurrent Pancreatitis. Trends Cardiovasc Med. 2020;30(2):80-5. doi: 10.1016\/j.tcm.2019.03.001.","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"key20251119150639_B101","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2016.02.019","article-title":"Severe Hypertriglyceridemia and Factors Associated with Acute Pancreatitis in an Integrated Health Care System","volume":"10","author":"Rashid","year":"2016","unstructured":"Rashid N, Sharma PP, Scott RD, Lin KJ, Toth PP. Severe Hypertriglyceridemia and Factors Associated with Acute Pancreatitis in an Integrated Health Care System. J Clin Lipidol. 2016;10(4):880-90. doi: 10.1016\/j.jacl.2016.02.019.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"key20251119150639_B102","doi-asserted-by":"crossref","first-page":"1234.e5","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing Familial Chylomicronemia Syndrome: Baseline Data of the APPROACH Study","volume":"12","author":"Blom","year":"2018","unstructured":"Blom DJ, O\u2019Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, et al. Characterizing Familial Chylomicronemia Syndrome: Baseline Data of the APPROACH Study. J Clin Lipidol. 2018;12(5):1234-43.e5. doi: 10.1016\/j.jacl.2018.05.013.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"key20251119150639_B103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14779072.2017.1311786","article-title":"The Burden of Familial Chylomicronemia Syndrome: Interim Results from the IN-FOCUS Study","volume":"15","author":"Davidson","year":"2017","unstructured":"Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. The Burden of Familial Chylomicronemia Syndrome: Interim Results from the IN-FOCUS Study. Expert Rev Cardiovasc Ther. 2017;15(5):415-23. doi: 10.1080\/14779072.2017.1311786.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key20251119150639_B104","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and Diagnosis of Patients with Familial Chylomicronaemia Syndrome (FCS): Expert Panel Recommendations and Proposal of an \"FCS Score\"","volume":"275","author":"Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, Arca M, Cefal\u00f9 AB, Noto D, et al. Identification and Diagnosis of Patients with Familial Chylomicronaemia Syndrome (FCS): Expert Panel Recommendations and Proposal of an \"FCS Score\". Atherosclerosis. 2018;275:265-72. doi: 10.1016\/j.atherosclerosis.2018.06.814.","journal-title":"Atherosclerosis"},{"issue":"5","key":"key20251119150639_B105","doi-asserted-by":"crossref","first-page":"101365","DOI":"10.1016\/j.gim.2025.101365","article-title":"Pathogenicity Assessment of Genetic Variants Identified in Patients with Severe Hypertriglyceridemia: Novel Cases of Familial Chylomicronemia Syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society","volume":"27","author":"Ariza","year":"2025","unstructured":"Ariza MJ, Coca-Prieto I, Rioja J, Mu\u00f1iz-Grijalvo O, Zamb\u00f3n-Rados D, Blanco-Echevarr\u00eda A, et al. Pathogenicity Assessment of Genetic Variants Identified in Patients with Severe Hypertriglyceridemia: Novel Cases of Familial Chylomicronemia Syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. Genet Med. 2025;27(5):101365. doi: 10.1016\/j.gim.2025.101365.","journal-title":"Genet Med"},{"issue":"2","key":"key20251119150639_B106","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacl.2023.01.005","article-title":"Role of Lipoprotein Lipase Activity Measurement in the Diagnosis of Familial Chylomicronemia Syndrome","volume":"17","author":"Rioja","year":"2023","unstructured":"Rioja J, Ariza MJ, Ben\u00edtez-Toledo MJ, Esp\u00edldora-Hern\u00e1ndez J, Coca-Prieto I, Arrobas-Velilla T, et al. Role of Lipoprotein Lipase Activity Measurement in the Diagnosis of Familial Chylomicronemia Syndrome. J Clin Lipidol. 2023;17(2):272-80. doi: 10.1016\/j.jacl.2023.01.005.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"key20251119150639_B107","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1194\/jlr.R120001116","article-title":"Chylomicronemia from GPIHBP1 Autoantibodies","volume":"61","author":"Miyashita","year":"2020","unstructured":"Miyashita K, Lutz J, Hudgins LC, Toib D, Ashraf AP, Song W, et al. Chylomicronemia from GPIHBP1 Autoantibodies. J Lipid Res. 2020;61(11):1365-76. doi: 10.1194\/jlr.R120001116.","journal-title":"J Lipid Res"},{"issue":"10","key":"key20251119150639_B108","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization Cardiovascular Disease Risk Charts: Revised Models to Estimate Risk in 21 Global Regions","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","unstructured":"WHO CVD Risk Chart Working Group. World Health Organization Cardiovascular Disease Risk Charts: Revised Models to Estimate Risk in 21 Global Regions. Lancet Glob Health. 2019;7(10):e1332-e1345. doi: 10.1016\/S2214-109X(19)30318-3.","journal-title":"Lancet Glob Health"},{"key":"key20251119150639_B109","first-page":"9","article-title":"Derivation, Internal Validation, and Recalibration of a Cardiovascular Risk Score for Latin America and the Caribbean (Globorisk-LAC): A Pooled Analysis of Cohort Studies","author":"Cohorts Consortium of Latin America and the Caribbean (CC-LAC)","year":"2022","unstructured":"Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Derivation, Internal Validation, and Recalibration of a Cardiovascular Risk Score for Latin America and the Caribbean (Globorisk-LAC): A Pooled Analysis of Cohort Studies. Lancet Reg Health Am. 2022;9. doi: 10.1016\/j.lana.2022.100258.","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"key20251119150639_B110","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and Validation of the American Heart Association's PREVENT Equations","volume":"149","author":"Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430-49. doi: 10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"issue":"24","key":"key20251119150639_B111","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement from the American Heart Association. Circulation. 2023;148(24):1982-2004. doi: 10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"issue":"18","key":"key20251119150639_B112","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.291.18.2204","article-title":"Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-Aged Adults: A Prospective Study of Parents and Offspring","volume":"291","author":"Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Nam BH, D\u2019Agostino RB Sr, Levy D, Murabito JM, Wang TJ, et al. Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-Aged Adults: A Prospective Study of Parents and Offspring. JAMA. 2004;291(18):2204-11. doi: 10.1001\/jama.291.18.2204.","journal-title":"JAMA"},{"issue":"34","key":"key20251119150639_B113","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1093\/eurheartj\/ehab454","article-title":"Association between Adiposity and Cardiovascular Outcomes: An Umbrella Review and Meta-Analysis of Observational and Mendelian Randomization Studies","volume":"42","author":"Kim","year":"2021","unstructured":"Kim MS, Kim WJ, Khera AV, Kim JY, Yon DK, Lee SW, et al. Association between Adiposity and Cardiovascular Outcomes: An Umbrella Review and Meta-Analysis of Observational and Mendelian Randomization Studies. Eur Heart J. 2021;42(34):3388-403. doi: 10.1093\/eurheartj\/ehab454.","journal-title":"Eur Heart J"},{"issue":"21","key":"key20251119150639_B114","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi: 10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"key20251119150639_B115","first-page":"S41","article-title":"Expert Panel Report: Guidelines (2013) for the Management of Overweight and Obesity in Adults","volume":"22","author":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013","year":"2014","unstructured":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert Panel Report: Guidelines (2013) for the Management of Overweight and Obesity in Adults. Obesity. 2014;22(Suppl 2):S41-410. doi: 10.1002\/oby.20660.","journal-title":"Obesity"},{"issue":"3","key":"key20251119150639_B116","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and Diagnostic Criteria of Clinical Obesity","volume":"13","author":"Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and Diagnostic Criteria of Clinical Obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-62. doi: 10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20251119150639_B117","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf314","article-title":"Clinical Staging to Guide Management of Metabolic Disorders and Their Sequelae: A European Atherosclerosis Society consensus Statement","author":"Romeo","year":"2025","unstructured":"Romeo S, Vidal-Puig A, Husain M, Ahima R, Arca M, Bhatt DL, et al. Clinical Staging to Guide Management of Metabolic Disorders and Their Sequelae: A European Atherosclerosis Society consensus Statement. Eur Heart J. 2025:ehaf314. doi: 10.1093\/eurheartj\/ehaf314.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20251119150639_B118","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The Metabolic Syndrome and Cardiovascular Risk a Systematic Review and Meta-Analysis","volume":"56","author":"Mottillo","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The Metabolic Syndrome and Cardiovascular Risk a Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2010;56(14):1113-32. doi: 10.1016\/j.jacc.2010.05.034.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20251119150639_B119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis","volume":"65","author":"Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis. J Hepatol. 2016;65(3):589-600. doi: 10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"issue":"12","key":"key20251119150639_B120","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2023.09.004","article-title":"The Cardiovascular Burden of Rheumatoid Arthritis - Implications for Treatment","volume":"136","author":"Schattner","year":"2023","unstructured":"Schattner A. The Cardiovascular Burden of Rheumatoid Arthritis - Implications for Treatment. Am J Med. 2023;136(12):1143-6. doi: 10.1016\/j.amjmed.2023.09.004.","journal-title":"Am J Med"},{"issue":"4","key":"key20251119150639_B121","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Awareness and Attention to Comorbidities","volume":"80","author":"Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Awareness and Attention to Comorbidities. J Am Acad Dermatol. 2019;80(4):1073-113. doi: 10.1016\/j.jaad.2018.11.058.","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"key20251119150639_B122","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","article-title":"Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus","volume":"77","author":"Yafasova","year":"2021","unstructured":"Yafasova A, Fosb\u00f8l EL, Schou M, Baslund B, Faurschou M, Docherty KF, et al. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. J Am Coll Cardiol. 2021;77(14):1717-27. doi: 10.1016\/j.jacc.2021.02.029.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20251119150639_B123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.amjmed.2022.08.012","article-title":"Inflammatory Bowel Disease and Cardiovascular Diseases","volume":"135","author":"Chen","year":"2022","unstructured":"Chen B, Collen LV, Mowat C, Isaacs KL, Singh S, Kane SV, et al. Inflammatory Bowel Disease and Cardiovascular Diseases. Am J Med. 2022;135(12):1453-60. doi: 10.1016\/j.amjmed.2022.08.012.","journal-title":"Am J Med"},{"issue":"2","key":"key20251119150639_B124","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/ATVBAHA.122.318232","article-title":"Cardiovascular Disease and Thrombosis in HIV Infection","volume":"43","author":"Perkins","year":"2023","unstructured":"Perkins MV, Joseph SB, Dittmer DP, Mackman N. Cardiovascular Disease and Thrombosis in HIV Infection. Arterioscler Thromb Vasc Biol. 2023;43(2):175-91. doi: 10.1161\/ATVBAHA.122.318232.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"key20251119150639_B125","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","article-title":"Meta-Analysis of Psoriasis, Cardiovascular Disease, and Associated Risk Factors","volume":"69","author":"Miller","year":"2013","unstructured":"Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-Analysis of Psoriasis, Cardiovascular Disease, and Associated Risk Factors. J Am Acad Dermatol. 2013;69(6):1014-24. doi: 10.1016\/j.jaad.2013.06.053.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"key20251119150639_B126","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global Burden of Atherosclerotic Cardiovascular Disease in People Living with HIV: Systematic Review and Meta-Analysis","volume":"138","author":"Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living with HIV: Systematic Review and Meta-Analysis. Circulation. 2018;138(11):1100-12. doi: 10.1161\/CIRCULATIONAHA.117.033369.","journal-title":"Circulation"},{"key":"key20251119150639_B127","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2024-324796","article-title":"Risk and Management of Cardiac Disease in Kidney and Liver Transplant Recipients","author":"Shroff","year":"2025","unstructured":"Shroff GR, Benjamin MM, Rangaswami J, Lentine KL. Risk and Management of Cardiac Disease in Kidney and Liver Transplant Recipients. Heart. 2025:heartjnl-2024-324796. doi: 10.1136\/heartjnl-2024-324796.","journal-title":"Heart"},{"issue":"1","key":"key20251119150639_B128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ije\/dyn251","article-title":"Age at Menarche, Total Mortality and Mortality from Ischaemic Heart Disease and Stroke: The Adventist Health Study, 1976-88","volume":"38","author":"Jacobsen","year":"2009","unstructured":"Jacobsen BK, Oda K, Knutsen SF, Fraser GE. Age at Menarche, Total Mortality and Mortality from Ischaemic Heart Disease and Stroke: The Adventist Health Study, 1976-88. Int J Epidemiol. 2009;38(1):245-52. doi: 10.1093\/ije\/dyn251.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"key20251119150639_B129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00125-019-4840-2","article-title":"Gestational Diabetes and the Risk of Cardiovascular Disease in Women: A Systematic Review and Meta-Analysis","volume":"62","author":"Kramer","year":"2019","unstructured":"Kramer CK, Campbell S, Retnakaran R. Gestational Diabetes and the Risk of Cardiovascular Disease in Women: A Systematic Review and Meta-Analysis. Diabetologia. 2019;62(6):905-14. doi: 10.1007\/s00125-019-4840-2.","journal-title":"Diabetologia"},{"issue":"2","key":"key20251119150639_B130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007809","article-title":"Preterm Delivery and Future Risk of Maternal Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"7","author":"Wu","year":"2018","unstructured":"Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O\u2019Brien S, et al. Preterm Delivery and Future Risk of Maternal Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2018;7(2):e007809. doi: 10.1161\/JAHA.117.007809.","journal-title":"J Am Heart Assoc"},{"key":"key20251119150639_B131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2024.03.035","article-title":"Miscarriage and Stillbirth in Relation to Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis","volume":"297","author":"Wang","year":"2024","unstructured":"Wang M, Zhang J, Yuan L, Hu H, Li T, Feng Y, et al. Miscarriage and Stillbirth in Relation to Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Eur J Obstet Gynecol Reprod Biol. 2024;297:1-7. doi: 10.1016\/j.ejogrb.2024.03.035.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"key20251119150639_B132","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at Natural Menopause and Risk of Incident Cardiovascular Disease: A Pooled Analysis of Individual Patient Data","volume":"4","author":"Zhu","year":"2019","unstructured":"Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at Natural Menopause and Risk of Incident Cardiovascular Disease: A Pooled Analysis of Individual Patient Data. Lancet Public Health. 2019;4(11):e553-e564. doi: 10.1016\/S2468-2667(19)30155-0.","journal-title":"Lancet Public Health"},{"issue":"4","key":"key20251119150639_B133","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality","volume":"302","author":"Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA. 2009;302(4):412-23. doi: 10.1001\/jama.2009.1063.","journal-title":"JAMA"},{"issue":"2","key":"key20251119150639_B134","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCOUTCOMES.108.831198","article-title":"C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study","volume":"1","author":"Wilson","year":"2008","unstructured":"Wilson PW, Pencina M, Jacques P, Selhub J, D\u2019Agostino R Sr, O\u2019Donnell CJ. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1(2):92-7. doi: 10.1161\/CIRCOUTCOMES.108.831198.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"key20251119150639_B135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","article-title":"C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-Analyses for the U.S. Preventive Services Task Force","volume":"151","author":"Buckley","year":"2009","unstructured":"Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-Analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-95. doi: 10.7326\/0003-4819-151-7-200910060-00009.","journal-title":"Ann Intern Med"},{"issue":"22","key":"key20251119150639_B136","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women","volume":"391","author":"Ridker","year":"2024","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024;391(22):2087-97. doi: 10.1056\/NEJMoa2405182.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B137","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf281","article-title":"LDL-cholesterol, Lipoprotein(a) and High-Sensitivity Low-Density Lipoprotein Cholesterol, Lipoprotein(a) and High-Sensitivity C-Reactive Protein are Independent Predictors of Cardiovascular Events","author":"Markus","year":"2025","unstructured":"Markus MRP, Ittermann T, Coronado JM, Schipf S, Bahls M, K\u00f6nemann S, ET AL. LDL-cholesterol, Lipoprotein(a) and High-Sensitivity Low-Density Lipoprotein Cholesterol, Lipoprotein(a) and High-Sensitivity C-Reactive Protein are Independent Predictors of Cardiovascular Events. Eur Heart J. 2025:ehaf281. doi: 10.1093\/eurheartj\/ehaf281.","journal-title":"Eur Heart J"},{"key":"key20251119150639_B138","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-Density Lipoprotein Cholesterol, C-Reactive Protein, and Lipoprotein(a) Universal One-Time Screening in Primary Prevention: The EPIC-Norfolk Study","author":"Kraaijenhof","year":"2025","unstructured":"Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, Hovingh GK, ET AL. Low-Density Lipoprotein Cholesterol, C-Reactive Protein, and Lipoprotein(a) Universal One-Time Screening in Primary Prevention: The EPIC-Norfolk Study. Eur Heart J. 2025:ehaf209. doi: 10.1093\/eurheartj\/ehaf209.","journal-title":"Eur Heart J"},{"issue":"41","key":"key20251119150639_B139","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1093\/eurheartj\/ehaa083","article-title":"High-Sensitivity Cardiac Troponin Assays for Cardiovascular Risk Stratification in the General Population","volume":"41","author":"Farmakis","year":"2020","unstructured":"Farmakis D, Mueller C, Apple FS. High-Sensitivity Cardiac Troponin Assays for Cardiovascular Risk Stratification in the General Population. Eur Heart J. 2020;41(41):4050-6. doi: 10.1093\/eurheartj\/ehaa083.","journal-title":"Eur Heart J"},{"issue":"15","key":"key20251119150639_B140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/eurjpc\/zwad187","article-title":"Improving 10-Year Cardiovascular Risk Prediction in Apparently Healthy People: Flexible Addition of Risk Modifiers on top of SCORE2","volume":"30","author":"Hageman","year":"2023","unstructured":"Hageman SHJ, Petitjaen C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, et al. Improving 10-Year Cardiovascular Risk Prediction in Apparently Healthy People: Flexible Addition of Risk Modifiers on top of SCORE2. Eur J Prev Cardiol. 2023;30(15):1705-14. doi: 10.1093\/eurjpc\/zwad187.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"key20251119150639_B141","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jacc.2020.05.057","article-title":"Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium","volume":"76","author":"Sandoval","year":"2020","unstructured":"Sandoval Y, Bielinski SJ, Daniels LB, Blaha MJ, Michos ED, DeFilippis AP, et al. Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium. J Am Coll Cardiol. 2020;76(4):357-70. doi: 10.1016\/j.jacc.2020.05.057.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20251119150639_B142","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death","volume":"350","author":"Wang","year":"2004","unstructured":"Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. N Engl J Med. 2004;350(7):655-63. doi: 10.1056\/NEJMoa031994.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20251119150639_B143","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic Peptides and Integrated Risk Assessment for Cardiovascular Disease: An Individual-Participant-Data Meta-Analysis","volume":"4","author":"Willeit","year":"2016","unstructured":"Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, et al. Natriuretic Peptides and Integrated Risk Assessment for Cardiovascular Disease: An Individual-Participant-Data Meta-Analysis. Lancet Diabetes Endocrinol. 2016;4(10):840-9. doi: 10.1016\/S2213-8587(16)30196-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"key20251119150639_B144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association Scientific Statement on Coronary Artery Calcium Scoring to Guide Preventive Strategies for ASCVD Risk Reduction","volume":"15","author":"Orringer","year":"2021","unstructured":"Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The National Lipid Association Scientific Statement on Coronary Artery Calcium Scoring to Guide Preventive Strategies for ASCVD Risk Reduction. J Clin Lipidol. 2021;15(1):33-60. doi: 10.1016\/j.jacl.2020.12.005.","journal-title":"J Clin Lipidol"},{"issue":"9","key":"key20251119150639_B145","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a Calcium Score Equate to Secondary Prevention?: Insights from the Multinational CONFIRM Registry","volume":"16","author":"Budoff","year":"2023","unstructured":"Budoff MJ, Kinninger A, Gransar H, Achenbach S, Al-Mallah M, Bax JJ, et al. When does a Calcium Score Equate to Secondary Prevention?: Insights from the Multinational CONFIRM Registry. JACC Cardiovasc Imaging. 2023;16(9):1181-9. doi: 10.1016\/j.jcmg.2023.03.008.","journal-title":"JACC Cardiovasc Imaging"},{"key":"key20251119150639_B146","article-title":"Revis\u00e3o sistem\u00e1tica sobre a influ\u00eancia da calcifica\u00e7\u00e3o da art\u00e9ria coron\u00e1ria na classifica\u00e7\u00e3o do risco cardiovascular em pacientes em preven\u00e7\u00e3o prim\u00e1ria: recomenda\u00e7\u00e3o da Sociedade Brasileira de Cardiologia","author":"Miname","year":"2025","unstructured":"Miname M, Santos R, Cesena F, Zorzanelli V, Sposito A, Saraiva JK, Rached FH. Revis\u00e3o sistem\u00e1tica sobre a influ\u00eancia da calcifica\u00e7\u00e3o da art\u00e9ria coron\u00e1ria na classifica\u00e7\u00e3o do risco cardiovascular em pacientes em preven\u00e7\u00e3o prim\u00e1ria: recomenda\u00e7\u00e3o da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2025. Ahead of print.","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"key20251119150639_B147","doi-asserted-by":"crossref","first-page":"100886","DOI":"10.1016\/j.jacadv.2024.100886","article-title":"Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis","volume":"3","author":"Qureshi","year":"2024","unstructured":"Qureshi H, Kaul P, Dover DC, Blaha MJ, Bellows BK, Mancini GBJ. Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis. JACC Adv. 2024;3(4):100886. doi: 10.1016\/j.jacadv.2024.100886.","journal-title":"JACC Adv"},{"issue":"8","key":"key20251119150639_B148","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamacardio.2020.1240","article-title":"Cost-Effectiveness of Contemporary Statin Use Guidelines with or without Coronary Artery Calcium Assessment in African American Individuals","volume":"5","author":"Spahillari","year":"2020","unstructured":"Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, et al. Cost-Effectiveness of Contemporary Statin Use Guidelines with or without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiol. 2020;5(8):871-80. doi: 10.1001\/jamacardio.2020.1240.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"key20251119150639_B149","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.36660\/abc.20210347","article-title":"Cost-Effectiveness of Using the Coronary Artery Calcium Score in Guiding Therapeutic Decisions in Primary Prevention in the Brazilian Population","volume":"118","author":"Val\u00e9rio","year":"2022","unstructured":"Val\u00e9rio RS, Generoso G, Fernandes JL, Nasir K, Hong JC, Bittencourt MS. Cost-Effectiveness of Using the Coronary Artery Calcium Score in Guiding Therapeutic Decisions in Primary Prevention in the Brazilian Population. Arq Bras Cardiol. 2022;118(6):1126-31. doi: 10.36660\/abc.20210347.","journal-title":"Arq Bras Cardiol"},{"issue":"8","key":"key20251119150639_B150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.echo.2020.04.021","article-title":"Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography","volume":"33","author":"Johri","year":"2020","unstructured":"Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):917-33. doi: 10.1016\/j.echo.2020.04.021.","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"key20251119150639_B151","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.2012.9630","article-title":"Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction: A Meta-Analysis","volume":"308","author":"Den Ruijter","year":"2012","unstructured":"Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction: A Meta-Analysis. JAMA. 2012;308(8):796-803. doi: 10.1001\/jama.2012.9630.","journal-title":"JAMA"},{"issue":"1","key":"key20251119150639_B152","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2011.06.044","article-title":"Carotid Plaque, Compared with Carotid Intima-Media Thickness, More Accurately Predicts Coronary Artery Disease Events: A Meta-Analysis","volume":"220","author":"Inaba","year":"2012","unstructured":"Inaba Y, Chen JA, Bergmann SR. Carotid Plaque, Compared with Carotid Intima-Media Thickness, More Accurately Predicts Coronary Artery Disease Events: A Meta-Analysis. Atherosclerosis. 2012;220(1):128-33. doi: 10.1016\/j.atherosclerosis.2011.06.044.","journal-title":"Atherosclerosis"},{"issue":"10","key":"key20251119150639_B153","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/eurjpc\/zwad139","article-title":"Carotid Ultrasound and Systematic Coronary Risk Assessment 2 in the Prediction of Cardiovascular Events","volume":"30","author":"Bao","year":"2023","unstructured":"Bao X, Xu B, Lind L, Engstr\u00f6m G. Carotid Ultrasound and Systematic Coronary Risk Assessment 2 in the Prediction of Cardiovascular Events. Eur J Prev Cardiol. 2023;30(10):1007-14. doi: 10.1093\/eurjpc\/zwad139.","journal-title":"Eur J Prev Cardiol"},{"issue":"9733","key":"key20251119150639_B154","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies","volume":"375","author":"Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. Lancet. 2010;375(9733):2215-22. doi: 10.1016\/S0140-6736(10)60484-9.","journal-title":"Lancet"},{"issue":"11","key":"key20251119150639_B155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.numecd.2018.07.005","article-title":"Diabetes Mellitus, Blood Glucose and the Risk of Heart Failure: A Systematic Review and Meta-Analysis of Prospective Studies","volume":"28","author":"Aune","year":"2018","unstructured":"Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes Mellitus, Blood Glucose and the Risk of Heart Failure: A Systematic Review and Meta-Analysis of Prospective Studies. Nutr Metab Cardiovasc Dis. 2018;28(11):1081-91. doi:10.1016\/j.numecd.2018.07.005.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"key20251119150639_B156","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","article-title":"Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine","volume":"133","author":"Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine. Circulation. 2016;133(11):1058-66. doi: 10.1161\/CIRCULATIONAHA.115.018844.","journal-title":"Circulation"},{"key":"key20251119150639_B157","volume-title":"Diretriz SBD 2024 \u2013 Manejo do Risco Cardiovascular: Dislipidemia [Internet]","author":"Izar","year":"2024","unstructured":"Izar MCO, Fonseca FAH, Faludi A\u00c1, Ara\u00fajo DB. Diretriz SBD 2024 \u2013 Manejo do Risco Cardiovascular: Dislipidemia [Internet]. S\u00e3o Paulo: Sociedade Brasileira de Diabetes; 2024 [cited 2025 Aug 26]. Available from: https:\/\/diretriz.diabetes.org.br\/manejo-do-risco-cardiovascular-dislipidemia\/."},{"issue":"6","key":"key20251119150639_B158","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.011719","article-title":"Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults","volume":"18","author":"Fravel","year":"2025","unstructured":"Fravel MA, Ernst ME, Woods RL, Orchard SG, Ganjali S, Wetmore JB, et al. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults. Circ Cardiovasc Qual Outcomes. 2025;18(6):e011719. doi: 10.1161\/CIRCOUTCOMES.124.011719.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"key20251119150639_B159","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP Risk Prediction Algorithms: Estimating Incident Cardiovascular Event Risk in Older Persons in Four Geographical Risk Regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular Risk Collaboration","year":"2021","unstructured":"SCORE2-OP working group and ESC Cardiovascular Risk Collaboration. SCORE2-OP Risk Prediction Algorithms: Estimating Incident Cardiovascular Event Risk in Older Persons in Four Geographical Risk Regions. Eur Heart J. 2021;42(25):2455-67. doi: 10.1093\/eurheartj\/ehab312.","journal-title":"Eur Heart J"},{"issue":"6","key":"key20251119150639_B160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age","volume":"113","author":"Lloyd-Jones","year":"2006","unstructured":"Lloyd-Jones DM, Leip EP, Larson MG, D\u2019Agostino RB, Beiser A, Wilson PW, et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. 2006;113(6):791-8. doi: 10.1161\/CIRCULATIONAHA.105.548206.","journal-title":"Circulation"},{"issue":"14","key":"key20251119150639_B161","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","article-title":"Prediction of Individual Lifetime Cardiovascular Risk and Potential Treatment Benefit: Development and Recalibration of the LIFE-CVD2 Model to Four European Risk Regions","volume":"31","author":"Hageman","year":"2024","unstructured":"Hageman SHJ, Kaptoge S, de Vries TI, Lu W, Kist JM, van Os HJA, et al. Prediction of Individual Lifetime Cardiovascular Risk and Potential Treatment Benefit: Development and Recalibration of the LIFE-CVD2 Model to Four European Risk Regions. Eur J Prev Cardiol. 2024;31(14):1690-9. doi: 10.1093\/eurjpc\/zwae174.","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"key20251119150639_B162","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement from the American Heart Association","volume":"139","author":"de Ferranti","year":"2019","unstructured":"de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement from the American Heart Association. Circulation. 2019;139(13):e603-e634. doi: 10.1161\/CIR.0000000000000618.","journal-title":"Circulation"},{"issue":"14","key":"key20251119150639_B163","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease","volume":"352","author":"LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med. 2005;352(14):1425-35. doi: 10.1056\/NEJMoa050461.","journal-title":"N Engl J Med"},{"issue":"15","key":"key20251119150639_B164","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","volume":"350","author":"Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. 2004;350(15):1495-504. doi: 10.1056\/NEJMoa040583.","journal-title":"N Engl J Med"},{"issue":"25","key":"key20251119150639_B165","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimiba Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimiba Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi: 10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"9753","key":"key20251119150639_B166","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials","volume":"376","author":"Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. Lancet. 2010;376(9753):1670-81. doi: 10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"issue":"12","key":"key20251119150639_B167","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis","volume":"316","author":"Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. doi: 10.1001\/jama.2016.13985.","journal-title":"JAMA"},{"issue":"18","key":"key20251119150639_B168","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi: 10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"key20251119150639_B169","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107. doi: 10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-10-20","article-title":"Non-HDL-Cholesterol as Valid Surrogate to Apolipoprotein B100 Measurement in Diabetes: Discriminant Ratio and Unbiased Equivalence","volume":"10","author":"Hermans","year":"2011","unstructured":"Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-Cholesterol as Valid Surrogate to Apolipoprotein B100 Measurement in Diabetes: Discriminant Ratio and Unbiased Equivalence. Cardiovasc Diabetol. 2011;10:20. doi: 10.1186\/1475-2840-10-20.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"key20251119150639_B171","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","unstructured":"Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, et al. Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496-517. doi: 10.1515\/cclm-2019-1253.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"key20251119150639_B172","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/clinchem\/hvac183","article-title":"To ApoB or Not to ApoB: New Arguments, but Basis for Widespread Implementation Remains Elusive","volume":"69","author":"Welsh","year":"2023","unstructured":"Welsh P, Sattar N. To ApoB or Not to ApoB: New Arguments, but Basis for Widespread Implementation Remains Elusive. Clin Chem. 2023;69(1):3-5. doi: 10.1093\/clinchem\/hvac183.","journal-title":"Clin Chem"},{"issue":"25","key":"key20251119150639_B173","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut-Points-a Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"37","author":"Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut-Points-a Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-58. doi: 10.1093\/eurheartj\/ehw152.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20251119150639_B174","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.105.567107","article-title":"Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study","volume":"113","author":"Kathiresan","year":"2006","unstructured":"Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20-9. doi: 10.1161\/CIRCULATIONAHA.105.567107.","journal-title":"Circulation"},{"issue":"3","key":"key20251119150639_B175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk","volume":"4","author":"Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45. doi: 10.1161\/CIRCOUTCOMES.110.959247.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"key20251119150639_B176","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels with Risk of Cardiovascular Events Among Patients Treated with Statins: A Meta-Analysis","volume":"307","author":"Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels with Risk of Cardiovascular Events Among Patients Treated with Statins: A Meta-Analysis. JAMA. 2012;307(12):1302-9. doi: 10.1001\/jama.2012.366.","journal-title":"JAMA"},{"issue":"2","key":"key20251119150639_B177","first-page":"160","article-title":"Non-HDL Cholesterol as a Metric of Good Quality of Care: Opportunities and Challenges","volume":"38","author":"Virani","year":"2011","unstructured":"Virani SS. Non-HDL Cholesterol as a Metric of Good Quality of Care: Opportunities and Challenges. Tex Heart Inst J. 2011;38(2):160-2.","journal-title":"Tex Heart Inst J"},{"issue":"32","key":"key20251119150639_B178","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi: 10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20251119150639_B179","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease","volume":"322","author":"Ference","year":"2019","unstructured":"Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-91. doi: 10.1001\/jama.2019.14120.","journal-title":"JAMA"},{"issue":"4","key":"key20251119150639_B180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants with Risk of Coronary Heart Disease","volume":"321","author":"Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants with Risk of Coronary Heart Disease. JAMA. 2019;321(4):364-73. doi: 10.1001\/jama.2018.20045.","journal-title":"JAMA"},{"key":"key20251119150639_B181","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf472","article-title":"Cumulative Exposure to Atherogenic Lipoprotein Particles in Young Adults and Subsequent Incident Atherosclerotic Cardiovascular Disease","author":"Zheutlin","year":"2025","unstructured":"Zheutlin AR, Handoo F, Luebbe S, Ning H, Sniderman A, Stone NJ, et al. Cumulative Exposure to Atherogenic Lipoprotein Particles in Young Adults and Subsequent Incident Atherosclerotic Cardiovascular Disease. Eur Heart J. 2025:ehaf472. doi: 10.1093\/eurheartj\/ehaf472.","journal-title":"Eur Heart J"},{"issue":"11","key":"key20251119150639_B182","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jacc.2024.05.070","article-title":"Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood","volume":"84","author":"Wilkins","year":"2024","unstructured":"Wilkins JT, Ning H, Allen NB, Zheutlin A, Shah NS, Feinstein MJ, et al. Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood. J Am Coll Cardiol. 2024;84(11):961-73. doi: 10.1016\/j.jacc.2024.05.070.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20251119150639_B183","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between Cumulative Low-Density Lipoprotein Cholesterol Exposure during Young Adulthood and Middle Age and Risk of Cardiovascular Events","volume":"6","author":"Zhang","year":"2021","unstructured":"Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DR Jr, Allen NB, et al. Association between Cumulative Low-Density Lipoprotein Cholesterol Exposure during Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiol. 2021;6(12):1406-13. doi: 10.1001\/jamacardio.2021.3508.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"key20251119150639_B184","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195-207. doi: 10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B185","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf048","article-title":"Reappraisal of Statin Primary Prevention Trials: Implications for Identification of the Statin-Eligible Primary Prevention Patient","author":"Mancini","year":"2025","unstructured":"Mancini GBJ, Ryomoto A, Yeoh E, Iatan I, Brunham LR, Hegele RA. Reappraisal of Statin Primary Prevention Trials: Implications for Identification of the Statin-Eligible Primary Prevention Patient. Eur J Prev Cardiol. 2025:zwaf048. doi: 10.1093\/eurjpc\/zwaf048.","journal-title":"Eur J Prev Cardiol"},{"issue":"9364","key":"key20251119150639_B186","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial","volume":"361","author":"Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial. Lancet. 2003;361(9364):1149-58. doi: 10.1016\/S0140-6736(03)12948-0.","journal-title":"Lancet"},{"issue":"1","key":"key20251119150639_B187","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL Cholesterol-Lowering Treatment Beyond Current Recommendations for the Prevention of Major Vascular Events: A Systematic Review and Meta-Analysis of Randomised Trials Including 327 037 Participants","volume":"8","author":"Wang","year":"2020","unstructured":"Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL Cholesterol-Lowering Treatment Beyond Current Recommendations for the Prevention of Major Vascular Events: A Systematic Review and Meta-Analysis of Randomised Trials Including 327 037 Participants. Lancet Diabetes Endocrinol. 2020;8(1):36-49. doi: 10.1016\/S2213-8587(19)30388-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"key20251119150639_B188","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/jamacardio.2018.3476","article-title":"A Long-Term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention","volume":"3","author":"Thanassoulis","year":"2018","unstructured":"Thanassoulis G, Sniderman AD, Pencina MJ. A Long-Term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA Cardiol. 2018;3(11):1090-1095. doi: 10.1001\/jamacardio.2018.3476.","journal-title":"JAMA Cardiol"},{"issue":"17","key":"key20251119150639_B189","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent Reduction in LDL Cholesterol Following High-Intensity Statin Therapy: Potential Implications for Guidelines and for the Prescription of Emerging Lipid-Lowering Agents","volume":"37","author":"Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L; JUPITER Trial Study Group. Percent Reduction in LDL Cholesterol Following High-Intensity Statin Therapy: Potential Implications for Guidelines and for the Prescription of Emerging Lipid-Lowering Agents. Eur Heart J. 2016;37(17):1373-9. doi: 10.1093\/eurheartj\/ehw046.","journal-title":"Eur Heart J"},{"issue":"9841","key":"key20251119150639_B190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials. Lancet. 2012;380(9841):581-90. doi: 10.1016\/S0140-6736(12)60367-5.","journal-title":"Lancet"},{"issue":"10349","key":"key20251119150639_B191","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-Term Efficacy and Safety of Moderate-Intensity Statin with Ezetimiba Combination Therapy versus High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease (RACING): A Randomised, Open-Label, Non-Inferiority Trial","volume":"400","author":"Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-Term Efficacy and Safety of Moderate-Intensity Statin with Ezetimiba Combination Therapy versus High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease (RACING): A Randomised, Open-Label, Non-Inferiority Trial. Lancet. 2022;400(10349):380-90. doi: 10.1016\/S0140-6736(22)00916-3.","journal-title":"Lancet"},{"issue":"19","key":"key20251119150639_B192","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.119.042551","article-title":"Risk Categorization Using New American College of Cardiology\/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes","volume":"140","author":"Roe","year":"2019","unstructured":"Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al. Risk Categorization Using New American College of Cardiology\/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019;140(19):1578-89. doi: 10.1161\/CIRCULATIONAHA.119.042551.","journal-title":"Circulation"},{"issue":"8","key":"key20251119150639_B193","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","unstructured":"Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis from FOURIER. Circulation. 2018;138(8):756-66. doi: 10.1161\/CIRCULATIONAHA.118.034309.","journal-title":"Circulation"},{"issue":"12","key":"key20251119150639_B194","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-92. doi: 10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"4","key":"key20251119150639_B195","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Circulation. 2018;137(4):338-50. doi: 10.1161\/CIRCULATIONAHA.117.032235.","journal-title":"Circulation"},{"issue":"12","key":"key20251119150639_B196","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-Onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial","volume":"5","author":"Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-Onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial. Lancet Diabetes Endocrinol. 2017;5(12):941-50. doi: 10.1016\/S2213-8587(17)30313-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"key20251119150639_B197","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of Alirocumab on Cardiovascular and Metabolic Outcomes after Acute Coronary Syndrome in Patients with or without Diabetes: A Prespecified Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial","volume":"7","author":"Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of Alirocumab on Cardiovascular and Metabolic Outcomes after Acute Coronary Syndrome in Patients with or without Diabetes: A Prespecified Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial. Lancet Diabetes Endocrinol. 2019;7(8):618-28. doi: 10.1016\/S2213-8587(19)30158-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10106","key":"key20251119150639_B198","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical Efficacy and Safety of Achieving Very low LDL-Cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial","volume":"390","author":"Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical Efficacy and Safety of Achieving Very low LDL-Cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial. Lancet. 2017;390(10106):1962-71. doi: 10.1016\/S0140-6736(17)32290-0.","journal-title":"Lancet"},{"issue":"5","key":"key20251119150639_B199","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-Term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","unstructured":"Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, et al. Long-Term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017;2(5):547-55. doi: 10.1001\/jamacardio.2017.0083.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"key20251119150639_B200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of Very Low Low-Density Lipoprotein Cholesterol Levels with Alirocumab: Pooled Data from Randomized Trials","volume":"69","author":"Robinson","year":"2017","unstructured":"Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels with Alirocumab: Pooled Data from Randomized Trials. J Am Coll Cardiol. 2017;69(5):471-82. doi: 10.1016\/j.jacc.2016.11.037.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20251119150639_B201","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2019.1681395","article-title":"Efficacy and Safety of PCSK9 Monoclonal Antibodies","volume":"18","author":"Iqbal","year":"2019","unstructured":"Iqbal Z, Dhage S, Mohamad JB, Abdel-Razik A, Donn R, Malik R, et al. Efficacy and Safety of PCSK9 Monoclonal Antibodies. Expert Opin Drug Saf. 2019;18(12):1191-201. doi: 10.1080\/14740338.2019.1681395.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"key20251119150639_B202","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive Function in a Randomized Trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-43. doi: 10.1056\/NEJMoa1701131.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20251119150639_B203","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400112","article-title":"Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab","volume":"4","author":"Zimerman","year":"2025","unstructured":"Zimerman A, O\u2019Donoghue ML, Ran X, Im K, Ott BR, Mach F, et al. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab. NEJM Evid. 2025;4(1):EVIDoa2400112. doi: 10.1056\/EVIDoa2400112.","journal-title":"NEJM Evid"},{"issue":"27","key":"key20251119150639_B204","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance Among apoB, Non-High-Density Lipoprotein Cholesterol, and Triglycerides: Implications for Cardiovascular Prevention","volume":"45","author":"Sniderman","year":"2024","unstructured":"Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance Among apoB, Non-High-Density Lipoprotein Cholesterol, and Triglycerides: Implications for Cardiovascular Prevention. Eur Heart J. 2024;45(27):2410-8. doi: 10.1093\/eurheartj\/ehae258.","journal-title":"Eur Heart J"},{"issue":"11","key":"key20251119150639_B205","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients","volume":"77","author":"Johannesen","year":"2021","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021;77(11):1439-50. doi: 10.1016\/j.jacc.2021.01.027.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"key20251119150639_B206","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","unstructured":"Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pe\u00f1a JM, et al. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663. doi: 10.1016\/j.jacl.2024.08.013.","journal-title":"J Clin Lipidol"},{"issue":"16","key":"key20251119150639_B207","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-Density Lipoprotein Revisited: Biological Functions and Clinical Relevance","volume":"44","author":"von Eckardstein","year":"2023","unstructured":"von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-Density Lipoprotein Revisited: Biological Functions and Clinical Relevance. Eur Heart J. 2023;44(16):1394-407. doi: 10.1093\/eurheartj\/ehac605.","journal-title":"Eur Heart J"},{"issue":"3","key":"key20251119150639_B208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the Relationship between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart Disease: A Multivariable Mendelian Randomisation Analysis","volume":"17","author":"Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Smith GD, et al. Evaluating the Relationship between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart Disease: A Multivariable Mendelian Randomisation Analysis. PLoS Med. 2020;17(3):e1003062. doi: 10.1371\/journal.pmed.1003062.","journal-title":"PLoS Med"},{"issue":"21","key":"key20251119150639_B209","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of Torcetrapib in Patients at High Risk for Coronary Events","volume":"357","author":"Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357(21):2109-22. doi: 10.1056\/NEJMoa0706628.","journal-title":"N Engl J Med"},{"issue":"22","key":"key20251119150639_B210","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome","volume":"367","author":"Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;367(22):2089-99. doi: 10.1056\/NEJMoa1206797.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20251119150639_B211","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease","volume":"376","author":"Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933-42. doi: 10.1056\/NEJMoa1609581.","journal-title":"N Engl J Med"},{"issue":"13","key":"key20251119150639_B212","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease","volume":"377","author":"Bowman","year":"2017","unstructured":"Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377(13):1217-27. doi: 10.1056\/NEJMoa1706444.","journal-title":"N Engl J Med"},{"issue":"24","key":"key20251119150639_B213","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy","volume":"365","author":"Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365(24):2255-67. doi: 10.1056\/NEJMoa1107579.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20251119150639_B214","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients","volume":"371","author":"Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371(3):203-12. doi: 10.1056\/NEJMoa1300955.","journal-title":"N Engl J Med"},{"issue":"9943","key":"key20251119150639_B215","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and Cardiovascular Disease","volume":"384","author":"Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and Cardiovascular Disease. Lancet. 2014;384(9943):626-35. doi: 10.1016\/S0140-6736(14)61177-6.","journal-title":"Lancet"},{"issue":"21","key":"key20251119150639_B216","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting Triglycerides Predict Recurrent Ischemic Events in Patients with Acute Coronary Syndrome Treated with Statins","volume":"65","author":"Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting Triglycerides Predict Recurrent Ischemic Events in Patients with Acute Coronary Syndrome Treated with Statins. J Am Coll Cardiol. 2015;65(21):2267-75. doi: 10.1016\/j.jacc.2015.03.544.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20251119150639_B217","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejim.2010.12.011","article-title":"Prevalence of Metabolic Syndrome and Cardiovascular Disease in a Hypertriglyceridemic Population","volume":"22","author":"Ascaso","year":"2011","unstructured":"Ascaso JF, Mill\u00e1n J, Mateo-Gallego R, Ruiz A, Suarez-Tembra M, Borrallo RM, et al. Prevalence of Metabolic Syndrome and Cardiovascular Disease in a Hypertriglyceridemic Population. Eur J Intern Med. 2011;22(2):177-81. doi: 10.1016\/j.ejim.2010.12.011.","journal-title":"Eur J Intern Med"},{"issue":"Suppl 8\u00aa","key":"key20251119150639_B218","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1016\/j.amjmed.2003.08.011","article-title":"Dyslipidemia in the Metabolic Syndrome and Type 2 Diabetes Mellitus","volume":"115","author":"Brunzell","year":"2003","unstructured":"Brunzell JD, Ayyobi AF. Dyslipidemia in the Metabolic Syndrome and Type 2 Diabetes Mellitus. Am J Med. 2003;115(Suppl 8\u00aa):24S-28S. doi: 10.1016\/j.amjmed.2003.08.011.","journal-title":"Am J Med"},{"issue":"24","key":"key20251119150639_B219","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32. doi: 10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20251119150639_B220","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick","year":"2023","unstructured":"Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2\/3. J Am Coll Cardiol. 2023;81(16):1633-45. doi: 10.1016\/j.jacc.2023.02.033.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"key20251119150639_B221","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and Net Reclassification of Cardiovascular Risk with Lipoprotein(a): Prospective 15-Year Outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","unstructured":"Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and Net Reclassification of Cardiovascular Risk with Lipoprotein(a): Prospective 15-Year Outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851-60. doi: 10.1016\/j.jacc.2014.03.061.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20251119150639_B222","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time has Come. A Scientific Statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time has Come. A Scientific Statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-92. doi: 10.1016\/j.jacl.2019.04.010.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"key20251119150639_B223","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-414. doi: 10.1016\/j.jacc.2019.03.009.","journal-title":"J Am Coll Cardiol"},{"issue":"10107","key":"key20251119150639_B224","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/S0140-6736(17)32252-3","article-title":"Associations of Fats and Carbohydrate Intake with Cardiovascular Disease and Mortality in 18 Countries from Five Continents (PURE): A Prospective Cohort Study","volume":"390","author":"Dehghan","year":"2017","unstructured":"Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of Fats and Carbohydrate Intake with Cardiovascular Disease and Mortality in 18 Countries from Five Continents (PURE): A Prospective Cohort Study. Lancet. 2017;390(10107):2050-62. doi: 10.1016\/S0140-6736(17)32252-3.","journal-title":"Lancet"},{"issue":"4","key":"key20251119150639_B225","first-page":"687","article-title":"The ARIC Investigators","volume":"129","author":"The Atherosclerosis Risk in Communities (ARIC) Study: Design and Objectives","year":"1989","unstructured":"The Atherosclerosis Risk in Communities (ARIC) Study: Design and Objectives. The ARIC Investigators. Am J Epidemiol. 1989;129(4):687-702.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"key20251119150639_B226","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2468-2667(18)30135-X","article-title":"Dietary Carbohydrate Intake and Mortality: A Prospective Cohort Study and Meta-Analysis","volume":"3","author":"Seidelmann","year":"2018","unstructured":"Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, et al. Dietary Carbohydrate Intake and Mortality: A Prospective Cohort Study and Meta-Analysis. Lancet Public Health. 2018;3(9):e419-e428. doi: 10.1016\/S2468-2667(18)30135-X.","journal-title":"Lancet Public Health"},{"issue":"5","key":"key20251119150639_B227","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report","volume":"42","author":"Evert","year":"2019","unstructured":"Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019;42(5):731-54. doi: 10.2337\/dci19-0014.","journal-title":"Diabetes Care"},{"key":"key20251119150639_B228","volume-title":"2015\u20132020 Dietary Guidelines for Americans","author":"U.S. Department of Health and Human Services. U.S. Department of Agriculture","year":"2015","unstructured":"U.S. Department of Health and Human Services. U.S. Department of Agriculture. 2015\u20132020 Dietary Guidelines for Americans. 8th ed. Washington: U.S. Department of Health and Human Services; 2015.","edition":"8th ed."},{"issue":"3","key":"key20251119150639_B229","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3945\/ajcn.2008.26285","article-title":"Saturated Fat, Carbohydrate, and Cardiovascular Disease","volume":"91","author":"Siri-Tarino","year":"2010","unstructured":"Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated Fat, Carbohydrate, and Cardiovascular Disease. Am J Clin Nutr. 2010;91(3):502-9. doi: 10.3945\/ajcn.2008.26285.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"key20251119150639_B230","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.advnut.2023.01.005","article-title":"Soluble Fiber Supplementation and Serum Lipid Profile: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials","volume":"14","author":"Ghavami","year":"2023","unstructured":"Ghavami A, Ziaei R, Talebi S, Barghchi H, Nattagh-Eshtivani E, Moradi S, et al. Soluble Fiber Supplementation and Serum Lipid Profile: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023;14(3):465-74. doi: 10.1016\/j.advnut.2023.01.005.","journal-title":"Adv Nutr"},{"issue":"9","key":"key20251119150639_B231","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1093\/jn\/nxab154","article-title":"An Oat \u03b2-Glucan Beverage Reduces LDL Cholesterol and Cardiovascular Disease Risk in Men and Women with Borderline High Cholesterol: A Double-Blind, Randomized, Controlled Clinical Trial","volume":"151","author":"Ms Wolever","year":"2021","unstructured":"Ms Wolever T, Rahn M, Dioum E, Spruill SE, Ezatagha A, Campbell JE, et al. An Oat \u03b2-Glucan Beverage Reduces LDL Cholesterol and Cardiovascular Disease Risk in Men and Women with Borderline High Cholesterol: A Double-Blind, Randomized, Controlled Clinical Trial. J Nutr. 2021;151(9):2655-66. doi: 10.1093\/jn\/nxab154.","journal-title":"J Nutr"},{"issue":"1","key":"key20251119150639_B232","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-Lowering Effects of Dietary Fiber: A Meta-Analysis","volume":"69","author":"Brown","year":"1999","unstructured":"Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-Lowering Effects of Dietary Fiber: A Meta-Analysis. Am J Clin Nutr. 1999;69(1):30-42. doi: 10.1093\/ajcn\/69.1.30.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"key20251119150639_B233","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.acvd.2015.09.005","article-title":"Dietary Fibre Intake and Mortality from Cardiovascular Disease and All Cancers: A Meta-Analysis of Prospective Cohort Studies","volume":"109","author":"Kim","year":"2016","unstructured":"Kim Y, Je Y. Dietary Fibre Intake and Mortality from Cardiovascular Disease and All Cancers: A Meta-Analysis of Prospective Cohort Studies. Arch Cardiovasc Dis. 2016;109(1):39-54. doi: 10.1016\/j.acvd.2015.09.005.","journal-title":"Arch Cardiovasc Dis"},{"issue":"7455","key":"key20251119150639_B234","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","article-title":"Mortality in Relation to Smoking: 50 Years\u2019 Observations on Male British Doctors","volume":"328","author":"Doll","year":"2004","unstructured":"Doll R, Peto R, Boreham J, Sutherland I. Mortality in Relation to Smoking: 50 Years\u2019 Observations on Male British Doctors. BMJ. 2004;328(7455):1519. doi: 10.1136\/bmj.38142.554479.AE.","journal-title":"BMJ"},{"issue":"7137","key":"key20251119150639_B235","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/bmj.316.7137.1043","article-title":"Smoking and Risk of Myocardial Infarction in Women and Men: Longitudinal Population Study","volume":"316","author":"Prescott","year":"1998","unstructured":"Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and Risk of Myocardial Infarction in Women and Men: Longitudinal Population Study. BMJ. 1998;316(7137):1043-7. doi: 10.1136\/bmj.316.7137.1043.","journal-title":"BMJ"},{"issue":"10","key":"key20251119150639_B236","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2003.12.047","article-title":"The Pathophysiology of Cigarette Smoking and Cardiovascular Disease: An Update","volume":"43","author":"Ambrose","year":"2004","unstructured":"Ambrose JA, Barua RS. The Pathophysiology of Cigarette Smoking and Cardiovascular Disease: An Update. J Am Coll Cardiol. 2004;43(10):1731-7. doi: 10.1016\/j.jacc.2003.12.047.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20251119150639_B237","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/jcb.24581","article-title":"Effects of Cigarette Smoking on HDL Quantity and Function: Implications for Atherosclerosis","volume":"114","author":"He","year":"2013","unstructured":"He BM, Zhao SP, Peng ZY. Effects of Cigarette Smoking on HDL Quantity and Function: Implications for Atherosclerosis. J Cell Biochem. 2013;114(11):2431-6. doi: 10.1002\/jcb.24581.","journal-title":"J Cell Biochem"},{"issue":"4","key":"key20251119150639_B238","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMsa1211128","article-title":"21st-Century Hazards of Smoking and Benefits of Cessation in the United States","volume":"368","author":"Jha","year":"2013","unstructured":"Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. N Engl J Med. 2013;368(4):341-50. doi: 10.1056\/NEJMsa1211128.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B239","volume-title":"Relat\u00f3rio de recomenda\u00e7\u00e3o n\u00ba 520, mar\u00e7o 2020","author":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas do Tabagismo","year":"2020","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas do Tabagismo. Relat\u00f3rio de recomenda\u00e7\u00e3o n\u00ba 520, mar\u00e7o 2020. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2020."},{"issue":"12","key":"key20251119150639_B240","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis","volume":"105","author":"Hasan","year":"2020","unstructured":"Hasan B, Nayfeh T, Alzuabi M, Wang Z, Kuchkuntla AR, Prokop LJ, et al. Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(12):dgaa673. doi: 10.1210\/clinem\/dgaa673.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20251119150639_B241","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, Dyslipidemia, and Cardiovascular Disease: A Joint Expert Review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays","year":"2024","unstructured":"Bays HE, Kirkpatrick CF, Maki KC, Toth PP, Morgan RT, Tondt J, et al. Obesity, Dyslipidemia, and Cardiovascular Disease: A Joint Expert Review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18(3):e320-e350. doi: 10.1016\/j.jacl.2024.04.001.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"key20251119150639_B242","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes","volume":"34","author":"Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. Diabetes Care. 2011;34(7):1481-6. doi: 10.2337\/dc10-2415.","journal-title":"Diabetes Care"},{"issue":"20","key":"key20251119150639_B243","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity Management in Adults: A Review","volume":"330","author":"Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023;330(20):2000-15. doi: 10.1001\/jama.2023.19897.","journal-title":"JAMA"},{"issue":"23","key":"key20251119150639_B244","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement from the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","unstructured":"Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement from the American Heart Association. Circulation. 2021;144(23):e472-e487. doi: 10.1161\/CIR.0000000000001031.","journal-title":"Circulation"},{"issue":"5","key":"key20251119150639_B245","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajcnut.2023.03.018","article-title":"Effect of Calorie Restriction in Comparison to Usual Diet or Usual Care on Remission of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"117","author":"Jayedi","year":"2023","unstructured":"Jayedi A, Zeraattalab-Motlagh S, Shahinfar H, Gregg EW, Shab-Bidar S. Effect of Calorie Restriction in Comparison to Usual Diet or Usual Care on Remission of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2023;117(5):870-82. doi: 10.1016\/j.ajcnut.2023.03.018.","journal-title":"Am J Clin Nutr"},{"key":"key20251119150639_B246","doi-asserted-by":"crossref","first-page":"m696","DOI":"10.1136\/bmj.m696","article-title":"Comparison of Dietary Macronutrient Patterns of 14 Popular Named Dietary Programmes for Weight and Cardiovascular Risk Factor Reduction in Adults: Systematic Review and Network Meta-Analysis of Randomised Trials","volume":"369","author":"Ge","year":"2020","unstructured":"Ge L, Sadeghirad B, Ball GDC, Costa BR, Hitchcock CL, Svendrovski A, et al. Comparison of Dietary Macronutrient Patterns of 14 Popular Named Dietary Programmes for Weight and Cardiovascular Risk Factor Reduction in Adults: Systematic Review and Network Meta-Analysis of Randomised Trials. BMJ. 2020;369:m696. doi: 10.1136\/bmj.m696.","journal-title":"BMJ"},{"issue":"14","key":"key20251119150639_B247","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/eurjpc\/zwad152","article-title":"Lifestyle Interventions to Change Trajectories of Obesity-Related Cardiovascular Risk from Childhood Onset to Manifestation in Adulthood: A Joint Scientific Statement of the Task Force for Childhood Health of the European Association of Preventive Cardiology and the European Childhood Obesity Group","volume":"30","author":"Hanssen","year":"2023","unstructured":"Hanssen H, Moholdt T, Bahls M, Biffi A, Siegrist M, Lewandowski AJ, et al. Lifestyle Interventions to Change Trajectories of Obesity-Related Cardiovascular Risk from Childhood Onset to Manifestation in Adulthood: A Joint Scientific Statement of the Task Force for Childhood Health of the European Association of Preventive Cardiology and the European Childhood Obesity Group. Eur J Prev Cardiol. 2023;30(14):1462-72. doi: 10.1093\/eurjpc\/zwad152.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"key20251119150639_B248","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41580-021-00411-4","article-title":"Molecular Mechanisms of Dietary Restriction Promoting Health and Longevity","volume":"23","author":"Green","year":"2022","unstructured":"Green CL, Lamming DW, Fontana L. Molecular Mechanisms of Dietary Restriction Promoting Health and Longevity. Nat Rev Mol Cell Biol. 2022;23(1):56-73. doi: 10.1038\/s41580-021-00411-4.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"key20251119150639_B249","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jpainsymman.2017.07.028","article-title":"State of the Science of Spirituality and Palliative Care Research Part I: Definitions, Measurement, and Outcomes","volume":"54","author":"Steinhauser","year":"2017","unstructured":"Steinhauser KE, Fitchett G, Handzo GF, Johnson KS, Koenig HG, Pargament KI, et al. State of the Science of Spirituality and Palliative Care Research Part I: Definitions, Measurement, and Outcomes. J Pain Symptom Manage. 2017;54(3):428-40. doi: 10.1016\/j.jpainsymman.2017.07.028.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"key20251119150639_B250","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5935\/1678-9741.20130015","article-title":"Religion, Spirituality and Cardiovascular Disease: Research, Clinical Implications, and Opportunities in Brazil","volume":"28","author":"Lucchese","year":"2013","unstructured":"Lucchese FA, Koenig HG. Religion, Spirituality and Cardiovascular Disease: Research, Clinical Implications, and Opportunities in Brazil. Rev Bras Cir Cardiovasc. 2013;28(1):103-28. doi: 10.5935\/1678-9741.20130015.","journal-title":"Rev Bras Cir Cardiovasc"},{"issue":"2","key":"key20251119150639_B251","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10943-018-0663-6","article-title":"Religiosity\/Spirituality and Physiological Markers of Health","volume":"59","author":"Shattuck","year":"2020","unstructured":"Shattuck EC, Muehlenbein MP. Religiosity\/Spirituality and Physiological Markers of Health. J Relig Health. 2020;59(2):1035-54. doi: 10.1007\/s10943-018-0663-6.","journal-title":"J Relig Health"},{"issue":"4","key":"key20251119150639_B252","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.explore.2011.04.005","article-title":"Impact of Spirituality\/Religiosity on Mortality: Comparison with Other Health Interventions","volume":"7","author":"Lucchetti","year":"2011","unstructured":"Lucchetti G, Lucchetti AL, Koenig HG. Impact of Spirituality\/Religiosity on Mortality: Comparison with Other Health Interventions. Explore. 2011;7(4):234-8. doi: 10.1016\/j.explore.2011.04.005.","journal-title":"Explore"},{"issue":"16","key":"key20251119150639_B253","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/CIRCULATIONAHA.119.044467","article-title":"Exercise and Coronary Atherosclerosis: Observations, Explanations, Relevance, and Clinical Management","volume":"141","author":"Aengevaeren","year":"2020","unstructured":"Aengevaeren VL, Mosterd A, Sharma S, Prakken NHJ, M\u00f6hlenkamp S, Thompson PD, et al. Exercise and Coronary Atherosclerosis: Observations, Explanations, Relevance, and Clinical Management. Circulation. 2020;141(16):1338-50. doi: 10.1161\/CIRCULATIONAHA.119.044467.","journal-title":"Circulation"},{"issue":"2","key":"key20251119150639_B254","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.0000109141.48980.37","article-title":"Physical Training Increases Endothelial Progenitor Cells, Inhibits Neointima Formation, and Enhances Angiogenesis","volume":"109","author":"Laufs","year":"2004","unstructured":"Laufs U, Werner N, Link A, Endres M, Wassmann S, J\u00fcrgens K, et al. Physical Training Increases Endothelial Progenitor Cells, Inhibits Neointima Formation, and Enhances Angiogenesis. Circulation. 2004;109(2):220-6. doi: 10.1161\/01.CIR.0000109141.48980.37.","journal-title":"Circulation"},{"issue":"6","key":"key20251119150639_B255","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1600-0838.2007.00748.x","article-title":"Aerobic Exercise Training Improves the Role of High-Density Lipoprotein Antioxidant and Reduces Plasma Lipid Peroxidation in Type 2 Diabetes Mellitus","volume":"18","author":"Iborra","year":"2008","unstructured":"Iborra RT, Ribeiro IC, Neves MQ, Charf AM, Lottenberg SA, Negr\u00e3o CE, et al. Aerobic Exercise Training Improves the Role of High-Density Lipoprotein Antioxidant and Reduces Plasma Lipid Peroxidation in Type 2 Diabetes Mellitus. Scand J Med Sci Sports. 2008;18(6):742-50. doi: 10.1111\/j.1600-0838.2007.00748.x.","journal-title":"Scand J Med Sci Sports"},{"issue":"11","key":"key20251119150639_B256","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi: 10.1161\/CIR.0000000000000678.","journal-title":"Circulation"},{"issue":"6","key":"key20251119150639_B257","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1249\/MSS.0000000000001939","article-title":"Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease","volume":"51","author":"Kraus","year":"2019","unstructured":"Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, et al. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc. 2019;51(6):1270-81. doi: 10.1249\/MSS.0000000000001939.","journal-title":"Med Sci Sports Exerc"},{"issue":"15","key":"key20251119150639_B258","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1177\/2047487319850718","article-title":"The Association of Resistance Training with Mortality: A Systematic Review and Meta-Analysis","volume":"26","author":"Saeidifard","year":"2019","unstructured":"Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, et al. The Association of Resistance Training with Mortality: A Systematic Review and Meta-Analysis. Eur J Prev Cardiol. 2019;26(15):1647-65. doi: 10.1177\/2047487319850718.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"key20251119150639_B259","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1249\/MSS.0000000000001822","article-title":"Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality","volume":"51","author":"Liu","year":"2019","unstructured":"Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, et al. Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality. Med Sci Sports Exerc. 2019;51(3):499-508. doi: 10.1249\/MSS.0000000000001822.","journal-title":"Med Sci Sports Exerc"},{"key":"key20251119150639_B260","first-page":"1","article-title":"The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition","author":"Powell","year":"2018","unstructured":"Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI, et al. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys Act Health. 2018:1-11. doi: 10.1123\/jpah.2018-0618.","journal-title":"J Phys Act Health"},{"issue":"10129","key":"key20251119150639_B261","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk Thresholds for Alcohol Consumption: Combined Analysis of Individual-Participant Data for 599 912 Current Drinkers in 83 Prospective Studies","volume":"391","author":"Wood","year":"2018","unstructured":"Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk Thresholds for Alcohol Consumption: Combined Analysis of Individual-Participant Data for 599 912 Current Drinkers in 83 Prospective Studies. Lancet. 2018;391(10129):1513-23. doi: 10.1016\/S0140-6736(18)30134-X.","journal-title":"Lancet"},{"issue":"10183","key":"key20251119150639_B262","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(18)31772-0","article-title":"Conventional and Genetic Evidence on Alcohol and Vascular Disease Aetiology: A Prospective Study of 500 000 Men and Women in China","volume":"393","author":"Millwood","year":"2019","unstructured":"Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and Genetic Evidence on Alcohol and Vascular Disease Aetiology: A Prospective Study of 500 000 Men and Women in China. Lancet. 2019;393(10183):1831-42. doi: 10.1016\/S0140-6736(18)31772-0.","journal-title":"Lancet"},{"key":"key20251119150639_B263","doi-asserted-by":"crossref","first-page":"g4164","DOI":"10.1136\/bmj.g4164","article-title":"Association between Alcohol and Cardiovascular Disease: Mendelian Randomisation Analysis Based on Individual Participant Data","volume":"349","author":"Holmes","year":"2014","unstructured":"Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between Alcohol and Cardiovascular Disease: Mendelian Randomisation Analysis Based on Individual Participant Data. BMJ. 2014;349:g4164. doi: 10.1136\/bmj.g4164.","journal-title":"BMJ"},{"key":"key20251119150639_B264","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nutres.2018.12.007","article-title":"Wine and Beer Within a Moderate Alcohol Intake is Associated with Higher Levels of HDL-c and Adiponectin","volume":"63","author":"Nova","year":"2019","unstructured":"Nova E, San Mauro-Mart\u00edn I, D\u00edaz-Prieto LE, Marcos A. Wine and Beer Within a Moderate Alcohol Intake is Associated with Higher Levels of HDL-c and Adiponectin. Nutr Res. 2019;63:42-50. doi: 10.1016\/j.nutres.2018.12.007.","journal-title":"Nutr Res"},{"issue":"4","key":"key20251119150639_B265","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/ejcn.2015.182","article-title":"The Effect of Moderate Alcohol Consumption on Biomarkers of Inflammation and Hemostatic Factors in Postmenopausal Women","volume":"70","author":"Stote","year":"2016","unstructured":"Stote KS, Tracy RP, Taylor PR, Baer DJ. The Effect of Moderate Alcohol Consumption on Biomarkers of Inflammation and Hemostatic Factors in Postmenopausal Women. Eur J Clin Nutr. 2016;70(4):470-4. doi: 10.1038\/ejcn.2015.182.","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"key20251119150639_B266","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/hr.2012.133","article-title":"Alcohol Consumption and Cardiovascular Disease Incidence in Men with and without Hypertension: The Suita Study","volume":"36","author":"Higashiyama","year":"2013","unstructured":"Higashiyama A, Okamura T, Watanabe M, Kokubo Y, Wakabayashi I, Okayama A, et al. Alcohol Consumption and Cardiovascular Disease Incidence in Men with and without Hypertension: The Suita Study. Hypertens Res. 2013;36(1):58-64. doi: 10.1038\/hr.2012.133.","journal-title":"Hypertens Res"},{"issue":"2","key":"key20251119150639_B267","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.diabet.2014.06.003","article-title":"Effects of Alcohol Consumption and the Metabolic Syndrome on 10-Year Incidence of Diabetes: The ATTICA Study","volume":"41","author":"Koloverou","year":"2015","unstructured":"Koloverou E, Panagiotakos DB, Pitsavos C, Chrysohoou C, Georgousopoulou EN, Metaxa V, et al. Effects of Alcohol Consumption and the Metabolic Syndrome on 10-Year Incidence of Diabetes: The ATTICA Study. Diabetes Metab. 2015;41(2):152-9. doi: 10.1016\/j.diabet.2014.06.003.","journal-title":"Diabetes Metab"},{"issue":"1","key":"key20251119150639_B268","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.numecd.2014.08.010","article-title":"Alcohol Consumption and Incidence of Type 2 Diabetes. Results from the CoLaus Study","volume":"25","author":"Marques-Vidal","year":"2015","unstructured":"Marques-Vidal P, Vollenweider P, Waeber G. Alcohol Consumption and Incidence of Type 2 Diabetes. Results from the CoLaus Study. Nutr Metab Cardiovasc Dis. 2015;25(1):75-84. doi: 10.1016\/j.numecd.2014.08.010.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"key20251119150639_B269","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.amjcard.2006.03.042","article-title":"A Meta-Analysis of the Effect of Soy Protein Supplementation on Serum Lipids","volume":"98","author":"Reynolds","year":"2006","unstructured":"Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A Meta-Analysis of the Effect of Soy Protein Supplementation on Serum Lipids. Am J Cardiol. 2006;98(5):633-40. doi: 10.1016\/j.amjcard.2006.03.042.","journal-title":"Am J Cardiol"},{"key":"key20251119150639_B270","first-page":"52","article-title":"Plant Sterols\/Stanols as Cholesterol Lowering Agents: A Meta-Analysis of Randomized Controlled Trials","author":"Abumweis","year":"2008","unstructured":"Abumweis SS, Barake R, Jones PJ. Plant Sterols\/Stanols as Cholesterol Lowering Agents: A Meta-Analysis of Randomized Controlled Trials. Food Nutr Res. 2008;52. doi: 10.3402\/fnr.v52i0.1811.","journal-title":"Food Nutr Res"},{"issue":"11","key":"key20251119150639_B271","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11883-021-00964-x","article-title":"Phytosterols and Cardiovascular Disease","volume":"23","author":"Makhmudova","year":"2021","unstructured":"Makhmudova U, Schulze PC, L\u00fctjohann D, Weing\u00e4rtner O. Phytosterols and Cardiovascular Disease. Curr Atheroscler Rep. 2021;23(11):68. doi: 10.1007\/s11883-021-00964-x.","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"key20251119150639_B272","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1253\/circj.70.1052","article-title":"Effect of Green Tea Consumption on Endothelial Function and Circulating Endothelial Progenitor Cells in Chronic Smokers","volume":"70","author":"Kim","year":"2006","unstructured":"Kim W, Jeong MH, Cho SH, Yun JH, Chae HJ, Ahn YK, et al. Effect of Green Tea Consumption on Endothelial Function and Circulating Endothelial Progenitor Cells in Chronic Smokers. Circ J. 2006;70(8):1052-7. doi: 10.1253\/circj.70.1052.","journal-title":"Circ J"},{"issue":"3","key":"key20251119150639_B273","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jnutbio.2006.12.005","article-title":"Green Tea as Inhibitor of the Intestinal Absorption of Lipids: Potential Mechanism for Its Lipid-Lowering Effect","volume":"18","author":"Koo","year":"2007","unstructured":"Koo SI, Noh SK. Green Tea as Inhibitor of the Intestinal Absorption of Lipids: Potential Mechanism for Its Lipid-Lowering Effect. J Nutr Biochem. 2007;18(3):179-83. doi: 10.1016\/j.jnutbio.2006.12.005.","journal-title":"J Nutr Biochem"},{"issue":"5","key":"key20251119150639_B274","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1017\/S0007114515005012","article-title":"Sesame Fractions and Lipid Profiles: A Systematic Review and Meta-Analysis of Controlled Trials","volume":"115","author":"Khalesi","year":"2016","unstructured":"Khalesi S, Paukste E, Nikbakht E, Khosravi-Boroujeni H. Sesame Fractions and Lipid Profiles: A Systematic Review and Meta-Analysis of Controlled Trials. Br J Nutr. 2016;115(5):764-73. doi: 10.1017\/S0007114515005012.","journal-title":"Br J Nutr"},{"issue":"6","key":"key20251119150639_B275","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/07853890.2015.1071872","article-title":"Effects of Probiotics Consumption on Lowering Lipids and CVD Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"47","author":"Sun","year":"2015","unstructured":"Sun J, Buys N. Effects of Probiotics Consumption on Lowering Lipids and CVD Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ann Med. 2015;47(6):430-40. doi: 10.3109\/07853890.2015.1071872.","journal-title":"Ann Med"},{"issue":"10","key":"key20251119150639_B276","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1017\/S000711451200373X","article-title":"Cholesterol-Lowering Efficacy of Lactobacillus Plantarum CECT 7527, 7528 and 7529 in Hypercholesterolaemic Adults","volume":"109","author":"Fuentes","year":"2013","unstructured":"Fuentes MC, Lajo T, Carri\u00f3n JM, Cu\u00f1\u00e9 J. Cholesterol-Lowering Efficacy of Lactobacillus Plantarum CECT 7527, 7528 and 7529 in Hypercholesterolaemic Adults. Br J Nutr. 2013;109(10):1866-72. doi: 10.1017\/S000711451200373X.","journal-title":"Br J Nutr"},{"issue":"4","key":"key20251119150639_B277","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ptr.1663","article-title":"Aged Garlic Extract Improves Endothelial Function in Men with Coronary Artery Disease","volume":"19","author":"Williams","year":"2005","unstructured":"Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA. Aged Garlic Extract Improves Endothelial Function in Men with Coronary Artery Disease. Phytother Res. 2005;19(4):314-9. doi: 10.1002\/ptr.1663.","journal-title":"Phytother Res"},{"issue":"1","key":"key20251119150639_B278","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ptr.8371","article-title":"Red Yeast Rice or Lovastatin? A Comparative Evaluation of Safety and Efficacy Through a Multifaceted Approach","volume":"39","author":"Rigillo","year":"2025","unstructured":"Rigillo G, Baini G, Bruni R, Puja G, Miraldi E, Pani L, et al. Red Yeast Rice or Lovastatin? A Comparative Evaluation of Safety and Efficacy Through a Multifaceted Approach. Phytother Res. 2025;39(1):264-81. doi: 10.1002\/ptr.8371.","journal-title":"Phytother Res"},{"issue":"19","key":"key20251119150639_B279","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. doi: 10.1001\/jama.285.19.2486.","journal-title":"JAMA"},{"issue":"21","key":"key20251119150639_B280","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","article-title":"Nutrition Committee. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease","volume":"106","author":"Kris-Etherton","year":"2002","unstructured":"Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation. 2002;106(21):2747-57. doi: 10.1161\/01.cir.0000038493.65177.94.","journal-title":"Circulation"},{"issue":"9493","key":"key20251119150639_B281","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins","volume":"366","author":"Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. Lancet. 2005;366(9493):1267-78. doi: 10.1016\/S0140-6736(05)67394-1.","journal-title":"Lancet"},{"issue":"34","key":"key20251119150639_B282","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of Statin Intolerance: A Meta-Analysis","volume":"43","author":"Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of Statin Intolerance: A Meta-Analysis. Eur Heart J. 2022;43(34):3213-23. doi: 10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"issue":"4","key":"key20251119150639_B283","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants from 135 Randomized, Controlled Trials","volume":"6","author":"Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants from 135 Randomized, Controlled Trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390-9. doi: 10.1161\/CIRCOUTCOMES.111.000071.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"15","key":"key20251119150639_B284","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of Adding Ezetimiba to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with versus without Diabetes Mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, et al. Benefit of Adding Ezetimiba to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with versus without Diabetes Mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571-82. doi: 10.1161\/CIRCULATIONAHA.117.030950.","journal-title":"Circulation"},{"issue":"2","key":"key20251119150639_B285","doi-asserted-by":"crossref","first-page":"226.e4","DOI":"10.1016\/j.clinthera.2017.12.018","article-title":"A Phase III, Multicenter, Randomized, Double-Blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy with Ezetimiba and Rosuvastatin versus Rosuvastatin Monotherapy in Patients with Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimiba for Hypercholesterolemia) Randomized Controlled Trial","volume":"40","author":"Hong","year":"2018","unstructured":"Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A Phase III, Multicenter, Randomized, Double-Blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy with Ezetimiba and Rosuvastatin versus Rosuvastatin Monotherapy in Patients with Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimiba for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018;40(2):226-241.e4. doi: 10.1016\/j.clinthera.2017.12.018.","journal-title":"Clin Ther"},{"issue":"16","key":"key20251119150639_B286","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192-203. doi: 10.1161\/CIRCULATIONAHA.122.063399.","journal-title":"Circulation"},{"issue":"15","key":"key20251119150639_B287","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease","volume":"146","author":"O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109-19. doi: 10.1161\/CIRCULATIONAHA.122.061620.","journal-title":"Circulation"},{"issue":"16","key":"key20251119150639_B288","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-19. doi: 10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"25","key":"key20251119150639_B289","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1161\/01.CIR.0000072345.98581.24","article-title":"Perspectives in Cholesterol-Lowering Therapy: The Role of Ezetimiba, a New Selective Inhibitor of Intestinal Cholesterol Absorption","volume":"107","author":"Bruckert","year":"2003","unstructured":"Bruckert E, Giral P, Tellier P. Perspectives in Cholesterol-Lowering Therapy: The Role of Ezetimiba, a New Selective Inhibitor of Intestinal Cholesterol Absorption. Circulation. 2003;107(25):3124-8. doi: 10.1161\/01.CIR.0000072345.98581.24.","journal-title":"Circulation"},{"issue":"2","key":"key20251119150639_B290","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1--Full Report","volume":"9","author":"Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1--Full Report. J Clin Lipidol. 2015;9(2):129-69. doi: 10.1016\/j.jacl.2015.02.003.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"key20251119150639_B291","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MOL.0000000000000390","article-title":"ATP-Citrate Lyase: Genetics, Molecular Biology and Therapeutic Target for Dyslipidemia","volume":"28","author":"Burke","year":"2017","unstructured":"Burke AC, Huff MW. ATP-Citrate Lyase: Genetics, Molecular Biology and Therapeutic Target for Dyslipidemia. Curr Opin Lipidol. 2017;28(2):193-200. doi: 10.1097\/MOL.0000000000000390.","journal-title":"Curr Opin Lipidol"},{"key":"key20251119150639_B292","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and Safety of Bempedoic Acid Added to Ezetimiba in Statin-Intolerant Patients with Hypercholesterolemia: A Randomized, Placebo-Controlled Study","volume":"277","author":"Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and Safety of Bempedoic Acid Added to Ezetimiba in Statin-Intolerant Patients with Hypercholesterolemia: A Randomized, Placebo-Controlled Study. Atherosclerosis. 2018;277:195-203. doi: 10.1016\/j.atherosclerosis.2018.06.002.","journal-title":"Atherosclerosis"},{"issue":"15","key":"key20251119150639_B293","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-64. doi: 10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20251119150639_B294","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk","volume":"393","author":"Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025;393(1):51-61. doi: 10.1056\/NEJMoa2415820.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20251119150639_B295","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacl.2025.04.167","article-title":"Effect of Obicetrapib on New-Onset Diabetes in Patients With Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the BROADWAY and BROOKLYN Trials","volume":"19","author":"Ray","year":"2025","unstructured":"Ray KK, Szarek M, Navar AM, Nelson AJ, Ballantyne CM, Kling D, et al. Effect of Obicetrapib on New-Onset Diabetes in Patients With Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the BROADWAY and BROOKLYN Trials. J Clin Lipidol. 2025;19(3):116-17. doi:10.1016\/j.jacl.2025.04.167.","journal-title":"J Clin Lipidol"},{"issue":"17","key":"key20251119150639_B296","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","article-title":"Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction","volume":"390","author":"Gibson","year":"2024","unstructured":"Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024;390(17):1560-71. doi: 10.1056\/NEJMoa2400969.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20251119150639_B297","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. Safety of Treatment, Changes in Risk Factors, And Incidence of Coronary Heart Disease","volume":"317","author":"Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. Safety of Treatment, Changes in Risk Factors, And Incidence of Coronary Heart Disease. N Engl J Med. 1987 Nov 12;317(20):1237-45. doi: 10.1056\/NEJM198711123172001. PMID: 3313041..","journal-title":"N Engl J Med"},{"issue":"12","key":"key20251119150639_B298","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events: VA-HIT: A Randomized Controlled Trial","volume":"285","author":"Robins","year":"2001","unstructured":"Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events: VA-HIT: A Randomized Controlled Trial. JAMA. 2001;285(12):1585-91. doi: 10.1001\/jama.285.12.1585.","journal-title":"JAMA"},{"issue":"9500","key":"key20251119150639_B299","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of Long-Term Fenofibrate Therapy on Cardiovascular Events in 9795 People with Type 2 Diabetes Mellitus (the FIELD Study): Randomised Controlled Trial","volume":"366","author":"Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of Long-Term Fenofibrate Therapy on Cardiovascular Events in 9795 People with Type 2 Diabetes Mellitus (the FIELD Study): Randomised Controlled Trial. Lancet. 2005;366(9500):1849-61. doi: 10.1016\/S0140-6736(05)67667-2.","journal-title":"Lancet"},{"issue":"17","key":"key20251119150639_B300","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus","volume":"362","author":"Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563-74. doi: 10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20251119150639_B301","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients with Coronary Artery Disease","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) study","year":"2000","unstructured":"Bezafibrate Infarction Prevention (BIP) study. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients with Coronary Artery Disease. Circulation. 2000;102(1):21-7. doi: 10.1161\/01.cir.102.1.21.","journal-title":"Circulation"},{"issue":"21","key":"key20251119150639_B302","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923-34. doi: 10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20251119150639_B303","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0091270009357432","article-title":"Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in BILE and Plasma in Healthy Volunteers","volume":"50","author":"Bergman","year":"2010","unstructured":"Bergman E, Matsson EM, Hedeland M, Bondesson U, Knutson L, Lennern\u00e4s H. Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in BILE and Plasma in Healthy Volunteers. J Clin Pharmacol. 2010;50(9):1039-49. doi: 10.1177\/0091270009357432.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"key20251119150639_B304","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"22","key":"key20251119150639_B305","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-80. doi: 10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"1","key":"key20251119150639_B306","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer","volume":"380","author":"Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23-32. doi: 10.1056\/NEJMoa1811403.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20251119150639_B307","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus","volume":"379","author":"Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540-50. doi: 10.1056\/NEJMoa1804989.","journal-title":"N Engl J Med"},{"issue":"9177","key":"key20251119150639_B308","first-page":"447","article-title":"Gruppo Italiano per lo Studio della Sopravvivenza Nell'infarto Miocardico","volume":"354","author":"Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Prevenzione Trial","year":"1999","unstructured":"Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Prevenzione Trial. Gruppo Italiano per lo Studio della Sopravvivenza Nell'infarto Miocardico. Lancet. 1999;354(9177):447-55.","journal-title":"Lancet"},{"issue":"21","key":"key20251119150639_B309","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction","volume":"363","author":"Kromhout","year":"2010","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. N Engl J Med. 2010;363(21):2015-26. doi: 10.1056\/NEJMoa1003603.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B310","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B Vitamins and Omega 3 Fatty Acids on Cardiovascular Diseases: A Randomised Placebo Controlled Trial","volume":"341","author":"Galan","year":"2010","unstructured":"Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B Vitamins and Omega 3 Fatty Acids on Cardiovascular Diseases: A Randomised Placebo Controlled Trial. BMJ. 2010;341:c6273. doi: 10.1136\/bmj.c6273.","journal-title":"BMJ"},{"issue":"12","key":"key20251119150639_B311","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691. doi: 10.1161\/CIR.0000000000000709.","journal-title":"Circulation"},{"issue":"9","key":"key20251119150639_B312","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline","volume":"97","author":"Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(9):2969-89. doi: 10.1210\/jc.2011-3213.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20251119150639_B313","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease","volume":"371","author":"J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. N Engl J Med. 2014;371(1):32-41. doi: 10.1056\/NEJMoa1308027.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20251119150639_B314","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease","volume":"371","author":"Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 2014;371(1):22-31. doi: 10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20251119150639_B315","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","unstructured":"Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, Gouni-Berthold I, et al. Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia. N Engl J Med. 2024;390(5):476-7. doi: 10.1056\/NEJMc2306575.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20251119150639_B316","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 Inhibition with Volanesorsen Reduces Hepatic Steatosis in Patients with Severe Hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","unstructured":"Prohaska TA, Alexander VJ, Karwatowska-Prokopczuk E, Tami J, Xia S, Witztum JL, et al. APOC3 Inhibition with Volanesorsen Reduces Hepatic Steatosis in Patients with Severe Hypertriglyceridemia. J Clin Lipidol. 2023;17(3):406-11. doi: 10.1016\/j.jacl.2023.04.007.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"key20251119150639_B317","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381(6):531-42. doi: 10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20251119150639_B318","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024;390(19):1781-92. doi: 10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20251119150639_B319","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770-80. doi: 10.1056\/NEJMoa2402309.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20251119150639_B320","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620-30. doi: 10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"key20251119150639_B321","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):899-912. doi: 10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20251119150639_B322","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med. 2025;392(2):127-37. doi: 10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20251119150639_B323","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 Deficiency and Protection Against Coronary Artery Disease","volume":"69","author":"Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol. 2017;69(16):2054-63. doi: 10.1016\/j.jacc.2017.02.030.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20251119150639_B324","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med. 2017;377(3):296-7. doi: 10.1056\/NEJMc1705994.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20251119150639_B325","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711-20. doi: 10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20251119150639_B326","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for Pediatric Patients with Homozygous Familial Hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for Pediatric Patients with Homozygous Familial Hypercholesterolemia. Circulation. 2024;149(5):343-53. doi: 10.1161\/CIRCULATIONAHA.123.065529.","journal-title":"Circulation"},{"key":"key20251119150639_B327","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment Gaps in the Implementation of LDL Cholesterol Control Among High- and Very High-Risk Patients in Europe between 2020 and 2021: The Multinational Observational SANTORINI Study","volume":"29","author":"Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment Gaps in the Implementation of LDL Cholesterol Control Among High- and Very High-Risk Patients in Europe between 2020 and 2021: The Multinational Observational SANTORINI Study. Lancet Reg Health Eur. 2023;29:100624. doi: 10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"key20251119150639_B328","first-page":"25","article-title":"Combination Therapy in the Guidelines: From High-Intensity Statins to High-Intensity Lipid-Lowering Therapies","volume":"1","author":"Masana","year":"2022","unstructured":"Masana L, Ibarretxe D, Andreychuk N, Royuela M, Rodr\u00edguez-Borjabad C, Plana N. Combination Therapy in the Guidelines: From High-Intensity Statins to High-Intensity Lipid-Lowering Therapies. Eur Ath J. 2022;1(1):25-9. doi:10.56095\/eaj.v1i1.10.","journal-title":"Eur Ath J"},{"issue":"8","key":"key20251119150639_B329","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination Lipid-Lowering Therapy as First-Line Strategy in Very High-Risk Patients","volume":"43","author":"Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS, et al. Combination Lipid-Lowering Therapy as First-Line Strategy in Very High-Risk Patients. Eur Heart J. 2022;43(8):830-3. doi: 10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"issue":"6","key":"key20251119150639_B330","first-page":"1018","article-title":"Alcance das Metas de Colesterol LDL ap\u00f3s Infarto Agudo do Mioc\u00e1rdio: Dados Reais do Sistema P\u00fablico de Sa\u00fade da Cidade de Curitiba","volume":"118","author":"Bernardi","year":"2022","unstructured":"Bernardi A, Olandoski M, Erbano LO, Guarita-Souza LC, Baena CP, Faria-Neto JR. Alcance das Metas de Colesterol LDL ap\u00f3s Infarto Agudo do Mioc\u00e1rdio: Dados Reais do Sistema P\u00fablico de Sa\u00fade da Cidade de Curitiba. Arq Bras Cardiol. 2022;118(6):1018-25. doi:10.36660\/abc.20210328.","journal-title":"Arq Bras Cardiol"},{"issue":"3","key":"key20251119150639_B331","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5935\/abc.20130062","article-title":"Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients: The REACT Study","volume":"100","author":"Berwanger","year":"2013","unstructured":"Berwanger O, Mattos LAP, Martin JF, Lopes RD, Figueiredo EL, Magnoni D, et al. Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients: The REACT Study. Arq Bras Cardiol. 2013;100(3):212-20. doi: 10.5935\/abc.20130062.","journal-title":"Arq Bras Cardiol"},{"issue":"12","key":"key20251119150639_B332","first-page":"939","article-title":"Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice. A clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC), in Collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice. A clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC), in Collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939-49. doi:10.1093\/ehjacc\/zuac123.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key20251119150639_B333","doi-asserted-by":"crossref","first-page":"100665","DOI":"10.1016\/j.lanepe.2023.100665","article-title":"Optimal Implementation of the 2019 ESC\/EAS Dyslipidaemia Guidelines in Patients with and without Atherosclerotic Cardiovascular Disease Across Europe: A Simulation Based on the DA VINCI Study","volume":"31","author":"Brandts","year":"2023","unstructured":"Brandts J, Bray S, Villa G, Catapano AL, Poulter NR, Vallejo-Vaz AJ, et al. Optimal Implementation of the 2019 ESC\/EAS Dyslipidaemia Guidelines in Patients with and without Atherosclerotic Cardiovascular Disease Across Europe: A Simulation Based on the DA VINCI Study. Lancet Reg Health Eur. 2023;31:100665. doi: 10.1016\/j.lanepe.2023.100665.","journal-title":"Lancet Reg Health Eur"},{"issue":"20","key":"key20251119150639_B334","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \"Inclisiran First\" Strategy vs Usual Care in Patients with Atherosclerotic Cardiovascular Disease","volume":"83","author":"Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An \"Inclisiran First\" Strategy vs Usual Care in Patients with Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024;83(20):1939-52. doi: 10.1016\/j.jacc.2024.03.382.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20251119150639_B335","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic Acid Plus Ezetimiba Fixed-Dose Combination in Patients with Hypercholesterolemia and High CVD Risk Treated with Maximally Tolerated Statin Therapy","volume":"27","author":"Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic Acid Plus Ezetimiba Fixed-Dose Combination in Patients with Hypercholesterolemia and High CVD Risk Treated with Maximally Tolerated Statin Therapy. Eur J Prev Cardiol. 2020;27(6):593-603. doi: 10.1177\/2047487319864671.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"key20251119150639_B336","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276898","article-title":"Simulation Study on LDL Cholesterol Target Attainment, Treatment Costs, and ASCVD Events with Bempedoic Acid in Patients at High and Very-High Cardiovascular Risk","volume":"17","author":"Katzmann","year":"2022","unstructured":"Katzmann JL, Becker C, Bilitou A, Laufs U. Simulation Study on LDL Cholesterol Target Attainment, Treatment Costs, and ASCVD Events with Bempedoic Acid in Patients at High and Very-High Cardiovascular Risk. PLoS One. 2022;17(10):e0276898. doi: 10.1371\/journal.pone.0276898.","journal-title":"PLoS One"},{"issue":"5","key":"key20251119150639_B337","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/cpt.3213","article-title":"Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance","volume":"115","author":"Li","year":"2024","unstructured":"Li JJ, Dou KF, Zhou ZG, Zhao D, Ye P, Chen H, et al. Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance. Clin Pharmacol Ther. 2024;115(5):954-64. doi: 10.1002\/cpt.3213.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"key20251119150639_B338","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The Nocebo Effect in the Context of Statin Intolerance","volume":"10","author":"Tobert","year":"2016","unstructured":"Tobert JA, Newman CB. The Nocebo Effect in the Context of Statin Intolerance. J Clin Lipidol. 2016;10(4):739-47. doi: 10.1016\/j.jacl.2016.05.002.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"key20251119150639_B339","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):38-81. doi: 10.1161\/ATV.0000000000000073.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"key20251119150639_B340","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of Statins on Skeletal Muscle Function","volume":"127","author":"Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of Statins on Skeletal Muscle Function. Circulation. 2013;127(1):96-103. doi: 10.1161\/CIRCULATIONAHA.112.136101.","journal-title":"Circulation"},{"issue":"4","key":"key20251119150639_B341","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype Standardization for Statin-Induced Myotoxicity","volume":"96","author":"Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype Standardization for Statin-Induced Myotoxicity. Clin Pharmacol Ther. 2014;96(4):470-6. doi: 10.1038\/clpt.2014.121.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"key20251119150639_B342","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-Associated Autoimmune Myopathy","volume":"374","author":"Mammen","year":"2016","unstructured":"Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016 Feb 18;374(7):664-9. doi: 10.1056\/NEJMra1515161.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20251119150639_B343","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/08971900211040291","article-title":"Statin-Associated Autoimmune Myopathy: Review of the Literature","volume":"36","author":"Barrons","year":"2023","unstructured":"Barrons R. Statin-Associated Autoimmune Myopathy: Review of the Literature. J Pharm Pract. 2023;36(2):383-93. doi: 10.1177\/08971900211040291.","journal-title":"J Pharm Pract"},{"issue":"1","key":"key20251119150639_B344","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in Non-Alcoholic Fatty Liver Disease and Chronically Elevated Liver Enzymes: A Histopathological Follow-Up Study","volume":"47","author":"Ekstedt","year":"2007","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in Non-Alcoholic Fatty Liver Disease and Chronically Elevated Liver Enzymes: A Histopathological Follow-Up Study. J Hepatol. 2007;47(1):135-41. doi: 10.1016\/j.jhep.2007.02.013.","journal-title":"J Hepatol"},{"issue":"3","key":"key20251119150639_B345","doi-asserted-by":"crossref","first-page":"101714","DOI":"10.1016\/j.beem.2022.101714","article-title":"Management of Patients with Statin Intolerance","volume":"37","author":"Martirossian","year":"2023","unstructured":"Martirossian AN, Goldberg AC. Management of Patients with Statin Intolerance. Best Pract Res Clin Endocrinol Metab. 2023;37(3):101714. doi: 10.1016\/j.beem.2022.101714.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"15","key":"key20251119150639_B346","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimiba in Patients with Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and Tolerability of Evolocumab vs Ezetimiba in Patients with Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-90. doi: 10.1001\/jama.2016.3608.","journal-title":"JAMA"},{"issue":"3","key":"key20251119150639_B347","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial","volume":"9","author":"Nicholls","year":"2024","unstructured":"Nicholls SJ, Nelson AJ, Lincoff AM, Brennan D, Ray KK, Cho L, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024;9(3):245-53. doi: 10.1001\/jamacardio.2023.5155.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"key20251119150639_B348","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/dtb.2009.07.0030","article-title":"Ezetimiba--an update","volume":"47","year":"2009","unstructured":"Ezetimiba--an update. Drug Ther Bull. 2009;47(8):91-5. doi: 10.1136\/dtb.2009.07.0030.","journal-title":"Drug Ther Bull"},{"issue":"1","key":"key20251119150639_B349","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamacardio.2022.4250","article-title":"Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo","volume":"8","author":"Hlatky","year":"2023","unstructured":"Hlatky MA, Gonzalez PE, Manson JE, Buring JE, Lee IM, Cook NR, et al. Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. JAMA Cardiol. 2023;8(1):74-80. doi: 10.1001\/jamacardio.2022.4250.","journal-title":"JAMA Cardiol"},{"issue":"23","key":"key20251119150639_B350","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review","volume":"49","author":"Marcoff","year":"2007","unstructured":"Marcoff L, Thompson PD. The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review. J Am Coll Cardiol. 2007;49(23):2231-7. doi: 10.1016\/j.jacc.2007.02.049.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20251119150639_B351","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A Randomized Trial of Coenzyme Q10 in Patients with Confirmed Statin Myopathy","volume":"238","author":"Taylor","year":"2015","unstructured":"Taylor BA, Lorson L, White CM, Thompson PD. A Randomized Trial of Coenzyme Q10 in Patients with Confirmed Statin Myopathy. Atherosclerosis. 2015;238(2):329-35. doi: 10.1016\/j.atherosclerosis.2014.12.016.","journal-title":"Atherosclerosis"},{"key":"key20251119150639_B352","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.006","article-title":"Effect of Coenzyme Q10 on Statin-Associated Myalgia and Adherence to Statin Therapy: A Systematic Review and Meta-Analysis","volume":"299","author":"Kennedy","year":"2020","unstructured":"Kennedy C, K\u00f6ller Y, Surkova E. Effect of Coenzyme Q10 on Statin-Associated Myalgia and Adherence to Statin Therapy: A Systematic Review and Meta-Analysis. Atherosclerosis. 2020;299:1-8. doi: 10.1016\/j.atherosclerosis.2020.03.006.","journal-title":"Atherosclerosis"},{"issue":"6","key":"key20251119150639_B353","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/fca-2021-0106","article-title":"Coenzyme Q10 Supplementation for the Treatment of Statin-Associated Muscle Symptoms","volume":"18","author":"Chen","year":"2022","unstructured":"Chen W, Ochs-Balcom HM, Ma C, Isackson PJ, Vladutiu GD, Luzum JA. Coenzyme Q10 Supplementation for the Treatment of Statin-Associated Muscle Symptoms. Future Cardiol. 2022;18(6):461-70. doi: 10.2217\/fca-2021-0106.","journal-title":"Future Cardiol"},{"issue":"8","key":"key20251119150639_B354","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0091270005278224","article-title":"Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics","volume":"45","author":"Simonson","year":"2005","unstructured":"Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics. J Clin Pharmacol. 2005;45(8):927-34. doi: 10.1177\/0091270005278224.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"key20251119150639_B355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1185\/03007995.2011.648264","article-title":"Effect of Pitavastatin vs. Rosuvastatin on International Normalized Ratio in Healthy Volunteers on Steady-State Warfarin","volume":"28","author":"Yu","year":"2012","unstructured":"Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, et al. Effect of Pitavastatin vs. Rosuvastatin on International Normalized Ratio in Healthy Volunteers on Steady-State Warfarin. Curr Med Res Opin. 2012;28(2):187-94. doi: 10.1185\/03007995.2011.648264.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"key20251119150639_B356","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/JTS.1000181","article-title":"An Updated Review of Interactions of Statins with Antibacterial and Antifungal Agents","volume":"3","author":"Eljaaly","year":"2017","unstructured":"Eljaaly K, Alshehri S. An Updated Review of Interactions of Statins with Antibacterial and Antifungal Agents. J Transl Sci. 2017;3(3):1-4. doi:10.15761\/JTS.1000181.","journal-title":"J Transl Sci"},{"key":"key20251119150639_B357","first-page":"A762","article-title":"Drug interaction Caused by Communication Problems. Rhabdomyolysis due to a Combination of Itraconazole and Simvastatin","volume":"154","author":"Tiessen","year":"2010","unstructured":"Tiessen RG, Lagerwey HJ, Jager GJ, Sprenger HG. Drug interaction Caused by Communication Problems. Rhabdomyolysis due to a Combination of Itraconazole and Simvastatin. Ned Tijdschr Geneeskd. 2010;154:A762.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"3","key":"key20251119150639_B358","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","article-title":"Effect of Fluconazole on Plasma Fluvastatin and Pravastatin Concentrations","volume":"56","author":"Kantola","year":"2000","unstructured":"Kantola T, Backman JT, Niemi M, Kivist\u00f6 KT, Neuvonen PJ. Effect of Fluconazole on Plasma Fluvastatin and Pravastatin Concentrations. Eur J Clin Pharmacol. 2000;56(3):225-9. doi: 10.1007\/s002280000127.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"key20251119150639_B359","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.farma.2009.08.004","article-title":"Approach to Establishing and Evaluating Clinical Relevance of Drug Interactions in HIV Patients: 2009 Update","volume":"34","author":"Giraldo","year":"2010","unstructured":"Giraldo NA, Amariles P, Guti\u00e9rrez FJ, Monsalve M, Faus MJ. Approach to Establishing and Evaluating Clinical Relevance of Drug Interactions in HIV Patients: 2009 Update. Farm Hosp. 2010;34(2):90-3. doi: 10.1016\/j.farma.2009.08.004.","journal-title":"Farm Hosp"},{"issue":"3","key":"key20251119150639_B360","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","article-title":"Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study","volume":"39","author":"Gerber","year":"2005","unstructured":"Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39(3):307-12. doi: 10.1097\/01.qai.0000167156.44980.33.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"key20251119150639_B361","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2710.2010.01184.x","article-title":"Simvastatin-Induced Myopathy, the Role of Interaction with Diltiazem and Genetic Predisposition","volume":"36","author":"Hu","year":"2011","unstructured":"Hu M, Mak VW, Tomlinson B. Simvastatin-Induced Myopathy, the Role of Interaction with Diltiazem and Genetic Predisposition. J Clin Pharm Ther. 2011;36(3):419-25. doi: 10.1111\/j.1365-2710.2010.01184.x.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"key20251119150639_B362","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1291\/hypres.28.223","article-title":"Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension","volume":"28","author":"Nishio","year":"2005","unstructured":"Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension. Hypertens Res. 2005;28(3):223-7. doi: 10.1291\/hypres.28.223.","journal-title":"Hypertens Res"},{"issue":"5","key":"key20251119150639_B363","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.clpt.6100098","article-title":"Amiodarone interacts with simvastatin but not with Pravastatin Disposition Kinetics","volume":"81","author":"Becquemont","year":"2007","unstructured":"Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, et al. Amiodarone interacts with simvastatin but not with Pravastatin Disposition Kinetics. Clin Pharmacol Ther. 2007;81(5):679-84. doi: 10.1038\/sj.clpt.6100098.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"key20251119150639_B364","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus","volume":"5","author":"Lemahieu","year":"2005","unstructured":"Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, et al. Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. Am J Transplant. 2005;5(9):2236-43. doi: 10.1111\/j.1600-6143.2005.01005.x.","journal-title":"Am J Transplant"},{"issue":"6","key":"key20251119150639_B365","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/gfq157","article-title":"Rhabdomyolysis and Acute Kidney Injury Secondary to Concomitant Use of Fluvastatin and Rapamycin in a Renal Transplant Recipient","volume":"25","author":"Basic-Jukic","year":"2010","unstructured":"Basic-Jukic N, Kes P, Bubic-Filipi L, Vranjican Z. Rhabdomyolysis and Acute Kidney Injury Secondary to Concomitant Use of Fluvastatin and Rapamycin in a Renal Transplant Recipient. Nephrol Dial Transplant. 2010;25(6):2036-7. doi: 10.1093\/ndt\/gfq157.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"key20251119150639_B366","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.27.4.603","article-title":"Simvastatin-Associated Rhabdomyolysis after Coadministration of Macrolide Antibiotics in two Patients","volume":"27","author":"Molden","year":"2007","unstructured":"Molden E, Andersson KS. Simvastatin-Associated Rhabdomyolysis after Coadministration of Macrolide Antibiotics in two Patients. Pharmacotherapy. 2007;27(4):603-7. doi: 10.1592\/phco.27.4.603.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"key20251119150639_B367","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/HCO.0b013e328338bc2d","article-title":"Lipid-Lowering Drugs and Heart Failure: Where do we Go after the Statin Trials?","volume":"25","author":"Strandberg","year":"2010","unstructured":"Strandberg TE. Lipid-Lowering Drugs and Heart Failure: Where do we Go after the Statin Trials? Curr Opin Cardiol. 2010;25(4):385-93. doi: 10.1097\/hco.0b013e328338bc2d.","journal-title":"Curr Opin Cardiol"},{"issue":"9645","key":"key20251119150639_B368","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of Rosuvastatin in Patients with Chronic Heart Failure (the GISSI-HF trial): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"372","author":"Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of Rosuvastatin in Patients with Chronic Heart Failure (the GISSI-HF trial): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. 2008;372(9645):1231-9. doi: 10.1016\/S0140-6736(08)61240-4.","journal-title":"Lancet"},{"issue":"12","key":"key20251119150639_B369","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin Discontinuation and Cardiovascular Events among Older People in Denmark","volume":"4","author":"Thompson","year":"2021","unstructured":"Thompson W, Morin L, Jarb\u00f8l DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin Discontinuation and Cardiovascular Events among Older People in Denmark. JAMA Netw Open. 2021;4(12):e2136802. doi: 10.1001\/jamanetworkopen.2021.36802.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"key20251119150639_B370","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13186","article-title":"Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy","volume":"4","author":"Rea","year":"2021","unstructured":"Rea F, Biffi A, Ronco R, Franchi M, Cammarota S, Citarella A, et al. Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. JAMA Netw Open. 2021;4(6):e2113186. doi: 10.1001\/jamanetworkopen.2021.13186.","journal-title":"JAMA Netw Open"},{"issue":"16","key":"key20251119150639_B371","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","article-title":"Alirocumab after Acute Coronary Syndrome in Patients with a History of Heart failure","volume":"43","author":"White","year":"2022","unstructured":"White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, et al. Alirocumab after Acute Coronary Syndrome in Patients with a History of Heart failure. Eur Heart J. 2022;43(16):1554-65. doi: 10.1093\/eurheartj\/ehab804.","journal-title":"Eur Heart J"},{"issue":"8","key":"key20251119150639_B372","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to Prevent Cardiovascular Disease in HIV Infection","volume":"389","author":"Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023;389(8):687-99. doi: 10.1056\/NEJMoa2304146.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20251119150639_B373","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-Infected Patients with Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study","volume":"75","author":"Boccara","year":"2020","unstructured":"Boccara F, Kumar PN, Caramelli B, Calmy A, L\u00f3pez JAG, Bray S, et al. Evolocumab in HIV-Infected Patients with Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. J Am Coll Cardiol. 2020;75(20):2570-84. doi: 10.1016\/j.jacc.2020.03.025.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20251119150639_B374","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029228","article-title":"Cardiovascular Risk Estimation Is Suboptimal in People With HIV","volume":"13","author":"Triant","year":"2024","unstructured":"Triant VA, Lyass A, Hurley LB, Borowsky LH, Ehrbar RQ, He W, et al. Cardiovascular Risk Estimation Is Suboptimal in People With HIV. J Am Heart Assoc. 2024;13(10):e029228. doi: 10.1161\/JAHA.123.029228.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"key20251119150639_B375","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2008.08.017","article-title":"Cardiovascular Prevention in HIV Patients: Results from a Successful Intervention Program","volume":"204","author":"Lima","year":"2009","unstructured":"Lima EM, Gualandro DM, Yu PC, Giuliano IC, Marques AC, Calderaro D, et al. Cardiovascular Prevention in HIV Patients: Results from a Successful Intervention Program. Atherosclerosis. 2009;204(1):229-32. doi: 10.1016\/j.atherosclerosis.2008.08.017.","journal-title":"Atherosclerosis"},{"key":"key20251119150639_B376","doi-asserted-by":"crossref","first-page":"132953","DOI":"10.1016\/j.ijcard.2024.132953","article-title":"Achieving LDL Goals in Patients with HIV: A Modern-Day Sisyphean Task?","volume":"422","author":"Cardozo","year":"2025","unstructured":"Cardozo FAM, Lottenberg MP, Caramelli B. Achieving LDL Goals in Patients with HIV: A Modern-Day Sisyphean Task? Int J Cardiol. 2025;422:132953. doi: 10.1016\/j.ijcard.2024.132953.","journal-title":"Int J Cardiol"},{"issue":"8","key":"key20251119150639_B377","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2337\/dc16-2388","article-title":"Patients with Diabetes without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment","volume":"40","author":"Olesen","year":"2017","unstructured":"Olesen KKW, Madsen M, Egholm G, Thim T, Jensen LO, Raungaard B, et al. Patients with Diabetes without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care. 2017;40(8):1103-10. doi:10.2337\/dc16-2388.","journal-title":"Diabetes Care"},{"issue":"4","key":"key20251119150639_B378","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00125-012-2817-5","article-title":"Revisiting the links between glycaemia, diabetes and cardiovascular disease","volume":"56","author":"Sattar","year":"2013","unstructured":"Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56(4):686-95. doi:10.1007\/s00125-012-2817-5.","journal-title":"Diabetologia"},{"issue":"7","key":"key20251119150639_B379","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","article-title":"Microvascular Disease and Risk of Cardiovascular Events among Individuals with Type 2 Diabetes: A Population-Level Cohort Study","volume":"4","author":"Brownrigg","year":"2016","unstructured":"Brownrigg JRW, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular Disease and Risk of Cardiovascular Events among Individuals with Type 2 Diabetes: A Population-Level Cohort Study. Lancet Diabetes Endocrinol. 2016;4(7):588-97. doi:10.1016\/S2213-8587(16)30057-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20251119150639_B380","volume-title":"Dyslipidemia in Patients with Diabetes","author":"Feingold","year":"2023","unstructured":"Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, editors. Endotext. South Dartmouth: MDText.com; 2023."},{"issue":"3","key":"key20251119150639_B381","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9 795 Individuals with Type 2 Diabetes and Various Components of the Metabolic Syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"32","author":"Scott","year":"2009","unstructured":"Scott R, O\u2019Brien R, Fulcher G, Pardy C, D\u2019Emden M, Taskinen MR, et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9 795 Individuals with Type 2 Diabetes and Various Components of the Metabolic Syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetes Care. 2009;32(3):493-98. doi:10.2337\/dc08-1543.","journal-title":"Diabetes Care"},{"issue":"10","key":"key20251119150639_B382","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","article-title":"Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study","volume":"35","author":"Boren","year":"2015","unstructured":"Boren J, Watts GF, Adiels M, Soderlund S, Chan DC, Hakkarainen A, et al. Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol. 2015;35(10):2218-224. doi:10.1161\/atvbaha.115.305614.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"key20251119150639_B383","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New Insights into the Pathophysiology of Dyslipidemia in Type 2 Diabetes","volume":"239","author":"Taskinen","year":"2015","unstructured":"Taskinen mr, bor\u00e9n j. New Insights into the Pathophysiology of Dyslipidemia in Type 2 Diabetes. Atherosclerosis. 2015;239(2):483-95. doi:10.1016\/j.atherosclerosis.2015.01.039.","journal-title":"Atherosclerosis"},{"issue":"9607","key":"key20251119150639_B384","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of Cholesterol-Lowering Therapy in 18 686 People with Diabetes in 14 Randomised Trials of Statins: A Meta-Analysis","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of Cholesterol-Lowering Therapy in 18 686 People with Diabetes in 14 Randomised Trials of Statins: A Meta-Analysis. Lancet. 2008;371(9607):117-25. doi:10.1016\/S0140-6736(08)60104-X.","journal-title":"Lancet"},{"issue":"25","key":"key20251119150639_B385","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi: 10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20251119150639_B386","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15650","article-title":"Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials","volume":"26","author":"Leiter","year":"2024","unstructured":"Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug;26(8):3223-3237. doi: 10.1111\/dom.15650.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"key20251119150639_B387","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of Fenofibrate Therapy with Long-Term Cardiovascular Risk in Statin-Treated Patients with Type 2 Diabetes","volume":"2","author":"Elam","year":"2017","unstructured":"Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. Association of Fenofibrate Therapy with Long-Term Cardiovascular Risk in Statin-Treated Patients with Type 2 Diabetes. JAMA Cardiol. 2017;2(4):370-80. doi:10.1001\/jamacardio.2016.4828.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"key20251119150639_B388","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jacc.2024.05.028","article-title":"Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis from PROMINENT","volume":"84","author":"Marinho","year":"2024","unstructured":"Marinho LL, Everett BM, Aday AW, Visseren FLJ, MacFadyen JG, Zaharris E, et al. Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis from PROMINENT. J Am Coll Cardiol. 2024;84(4):408-10. doi: 10.1016\/j.jacc.2024.05.028.","journal-title":"J Am Coll Cardiol"},{"key":"key20251119150639_B389","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2019.02.030","article-title":"Microvascular Complications in Diabetes: A Growing Concern for Cardiologists","volume":"291","author":"Avogaro","year":"2019","unstructured":"Avogaro A, Fadini GP. Microvascular Complications in Diabetes: A Growing Concern for Cardiologists. Int J Cardiol. 2019;291:29-35. doi: 10.1016\/j.ijcard.2019.02.030.","journal-title":"Int J Cardiol"},{"issue":"8","key":"key20251119150639_B390","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of Fenofibrate on Progression of Diabetic Retinopathy","volume":"3","author":"Preiss","year":"2024","unstructured":"Preiss D, Logue J, Sammons E, Zayed M, Emberson J, Wade R, et al. Effect of Fenofibrate on Progression of Diabetic Retinopathy. NEJM Evidence. 2024;3(8):EVIDoa2400179. doi: 10.1056\/EVIDoa2400179.","journal-title":"NEJM Evidence"},{"issue":"10101","key":"key20251119150639_B391","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","article-title":"Hypothyroidism","volume":"390","author":"Chaker","year":"2017","unstructured":"Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-62. doi: 10.1016\/S0140-6736(17)30703-1.","journal-title":"Lancet"},{"key":"key20251119150639_B392","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/bmb\/ldr030","article-title":"The Epidemiology of Thyroid Disease","volume":"99","author":"Vanderpump","year":"2011","unstructured":"Vanderpump MP. The Epidemiology of Thyroid Disease. Br Med Bull. 2011;99:39-51. doi: 10.1093\/bmb\/ldr030.","journal-title":"Br Med Bull"},{"issue":"4","key":"key20251119150639_B393","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.trsl.2007.12.006","article-title":"Lipid Profile in Different Degrees of Hypothyroidism and Effects of Levothyroxine Replacement in Mild Thyroid Failure","volume":"151","author":"Teixeira","year":"2008","unstructured":"Teixeira PFS, Reuters VS, Ferreira MM, Almeida CP, Reis FAA, Buescu A, et al. Lipid Profile in Different Degrees of Hypothyroidism and Effects of Levothyroxine Replacement in Mild Thyroid Failure. Transl Res. 2008;151(4):224-31. doi:10.1016\/j.trsl.2007.12.006.","journal-title":"Transl Res"},{"issue":"4","key":"key20251119150639_B394","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7150\/ijms.7104","article-title":"The Relationships between Thyroid Hormones and Thyroid-Stimulating Hormone with Lipid Profile in Euthyroid Men","volume":"11","author":"Chin","year":"2014","unstructured":"Chin KY, Ima-Nirwana S, Mohamed IN, Aminuddin A, Johari MH, Ngah WZ. The Relationships between Thyroid Hormones and Thyroid-Stimulating Hormone with Lipid Profile in Euthyroid Men. Int J Med Sci. 2014;11(4):349-55. doi: 10.7150\/ijms.7104.","journal-title":"Int J Med Sci"},{"key":"key20251119150639_B395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cca.2022.01.006","article-title":"Hyperlipidemia and Hypothyroidism","volume":"527","author":"Su","year":"2022","unstructured":"Su X, Peng H, Chen X, Wu X, Wang B. Hyperlipidemia and Hypothyroidism. Clin Chim Acta. 2022;527:61-70. doi: 10.1016\/j.cca.2022.01.006.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"key20251119150639_B396","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2265.2011.04328.x","article-title":"Thyroid Function and Prevalent and Incident Metabolic Syndrome in Older Adults: the Health, Ageing and Body Composition Study","volume":"76","author":"Waring","year":"2012","unstructured":"Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I, et al. Thyroid Function and Prevalent and Incident Metabolic Syndrome in Older Adults: the Health, Ageing and Body Composition Study. Clin Endocrinol. 2012;76(6):911-8. doi: 10.1111\/j.1365-2265.2011.04328.x.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"key20251119150639_B397","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","article-title":"Hypothyroidism as a Risk Factor for Statin Intolerance","volume":"8","author":"Robison","year":"2014","unstructured":"Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, et al. Hypothyroidism as a Risk Factor for Statin Intolerance. J Clin Lipidol. 2014;8(4):401-7. doi: 10.1016\/j.jacl.2014.05.005.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"key20251119150639_B398","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0002","article-title":"Update on Dyslipidemia in Hypothyroidism: The Mechanism of Dyslipidemia in Hypothyroidism","volume":"11","author":"Liu","year":"2022","unstructured":"Liu H, Peng D. Update on Dyslipidemia in Hypothyroidism: The Mechanism of Dyslipidemia in Hypothyroidism. Endocr Connect. 2022;11(2):e210002. doi: 10.1530\/EC-21-0002.","journal-title":"Endocr Connect"},{"issue":"12","key":"key20251119150639_B399","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis","volume":"105","author":"Kotwal","year":"2020","unstructured":"Kotwal A, Cortes T, Genere N, Hamidi O, Jasim S, Newman CB, et al. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020;105(12):dgaa672. doi: 10.1210\/clinem\/dgaa672.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20251119150639_B400","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014840","article-title":"Statins and All-Cause Mortality in Patients Undergoing Hemodialysis","volume":"9","author":"Jung","year":"2020","unstructured":"Jung J, Bae GH, Kang M, Kim SW, Lee DH. Statins and All-Cause Mortality in Patients Undergoing Hemodialysis. J Am Heart Assoc. 2020;9(5):e014840. doi:10.1161\/JAHA.119.014840.","journal-title":"J Am Heart Assoc"},{"key":"key20251119150639_B401","volume-title":"Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. London: NICE; 2023."},{"issue":"4 Suppl","key":"key20251119150639_B402","first-page":"117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):117-314. doi:10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"24","key":"key20251119150639_B403","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):285-350. doi: 10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"key20251119150639_B404","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/nep.14295","article-title":"Australian and New Zealand Living Guideline Cholesterol-Lowering Therapy for People with Chronic Kidney Disease (CARI Guidelines): Reducing the Evidence-Practice Gap","volume":"29","author":"Cashmore","year":"2024","unstructured":"Cashmore B, Tunnicliffe DJ, Palmer S, Blythen L, Boag J, Kostner K, et al. Australian and New Zealand Living Guideline Cholesterol-Lowering Therapy for People with Chronic Kidney Disease (CARI Guidelines): Reducing the Evidence-Practice Gap. Nephrology. 2024;29(8):495-509. doi: 10.1111\/nep.14295.","journal-title":"Nephrology"},{"issue":"9784","key":"key20251119150639_B405","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The Effects of Lowering LDL Cholesterol with Simvastatin Plus Ezetimiba in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial","volume":"377","author":"Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The Effects of Lowering LDL Cholesterol with Simvastatin Plus Ezetimiba in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. Lancet. 2011;377(9784):2181-92. doi: 10.1016\/S0140-6736(11)60739-3.","journal-title":"Lancet"},{"issue":"1","key":"key20251119150639_B406","article-title":"HMG CoA Reductase Inhibitors (Statins) for Kidney Transplant Recipients","volume":"2014","author":"Palmer","year":"2014","unstructured":"Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, et al. HMG CoA Reductase Inhibitors (Statins) for Kidney Transplant Recipients. Cochrane Database Syst Rev. 2014;2014(1):CD005019. doi: 10.1002\/14651858.CD005019.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"key20251119150639_B407","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis","volume":"353","author":"Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med. 2005;353(3):238-48. doi: 10.1056\/NEJMoa043545.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20251119150639_B408","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056\/NEJMoa0810177.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20251119150639_B409","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline","volume":"160","author":"Tonelli","year":"2014","unstructured":"Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2014;160(3):182. doi: 10.7326\/M13-2453.","journal-title":"Ann Intern Med"},{"issue":"16","key":"key20251119150639_B410","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/nu16162781","article-title":"Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management","volume":"16","author":"Gallo","year":"2024","unstructured":"Gallo G, Desideri G, Savoia C. Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management. Nutrients. 2024;16(16):2781. doi: 10.3390\/nu16162781.","journal-title":"Nutrients"},{"issue":"4","key":"key20251119150639_B411","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s13679-016-0235-6","article-title":"Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function","volume":"5","author":"Alpert","year":"2016","unstructured":"Alpert MA, Omran J, Bostick BP. Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. Curr Obes Rep. 2016;5(4):424-34. doi: 10.1007\/s13679-016-0235-6.","journal-title":"Curr Obes Rep"},{"issue":"9497","key":"key20251119150639_B412","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","article-title":"Obesity and the Risk of Myocardial Infarction in 27,000 Participants from 52 Countries: A Case-Control Study","volume":"366","author":"Yusuf","year":"2005","unstructured":"Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the Risk of Myocardial Infarction in 27,000 Participants from 52 Countries: A Case-Control Study. Lancet. 2005;366(9497):1640-9. doi: 10.1016\/S0140-6736(05)67663-5.","journal-title":"Lancet"},{"issue":"6","key":"key20251119150639_B413","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1373\/clinchem.2007.100156","article-title":"The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences","volume":"54","author":"Ferranti","year":"2008","unstructured":"Ferranti S, Mozaffarian D. The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences. Clin Chem. 2008;54(6):945-55. doi: 10.1373\/clinchem.2007.100156.","journal-title":"Clin Chem"},{"issue":"7","key":"key20251119150639_B414","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of Very Low-Density Lipoproteins is the Hallmark of the Dyslipidemia in the Metabolic Syndrome","volume":"28","author":"Adiels","year":"2008","unstructured":"Adiels M, Olofsson SO, Taskinen MR, Bor\u00e9n J. Overproduction of Very Low-Density Lipoproteins is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225-36. doi: 10.1161\/ATVBAHA.107.160192.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"key20251119150639_B415","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","unstructured":"Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013;369(2):145-54. doi: 10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"issue":"10170","key":"key20251119150639_B416","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and Safety of Statin Therapy in Older People: A Meta-Analysis of Individual Participant data from 28 Randomised Controlled Trials","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and Safety of Statin Therapy in Older People: A Meta-Analysis of Individual Participant data from 28 Randomised Controlled Trials. Lancet. 2019;393(10170):407-15. doi: 10.1016\/S0140-6736(18)31942-1.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"key20251119150639_B417","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin Hormones: Their Role in Health and Disease","volume":"20","author":"Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin Hormones: Their Role in Health and Disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21. doi: 10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"key20251119150639_B418","article-title":"Long-Term Weight Loss in the SELECT Trial: Semaglutide 2.4 mg vs Placebo Over 208 Weeks in a Global Population of 17 604 Participants","volume":"17","author":"Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J. Long-Term Weight Loss in the SELECT Trial: Semaglutide 2.4 mg vs Placebo Over 208 Weeks in a Global Population of 17 604 Participants. Obes Facts. 2024;17(Suppl 1):TS12.02.","journal-title":"Obes Facts"},{"issue":"1","key":"key20251119150639_B419","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric Surgery and Long-Term Cardiovascular Events","volume":"307","author":"Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m CD, Karason K, Wedel H, et al. Bariatric Surgery and Long-Term Cardiovascular Events. JAMA. 2012;307(1):56-65. doi: 10.1001\/jama.2011.1914.","journal-title":"JAMA"},{"issue":"8","key":"key20251119150639_B420","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/CIRCRESAHA.111.246876","article-title":"The Intersection between Aging and Cardiovascular Disease","volume":"110","author":"North","year":"2012","unstructured":"North BJ, Sinclair DA. The Intersection between Aging and Cardiovascular Disease. Circ Res. 2012;110(8):1097-108. doi: 10.1161\/CIRCRESAHA.111.246876.","journal-title":"Circ Res"},{"issue":"1","key":"key20251119150639_B421","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00392-016-1023-8","article-title":"Personalized Absolute Benefit of Statin Treatment for Primary or Secondary Prevention of Vascular Disease in Individual Elderly Patients","volume":"106","author":"Stam-Slob","year":"2017","unstructured":"Stam-Slob MC, Visseren FL, Jukema JW, van der Graaf Y, Poulter NR, Gupta A, et al. Personalized Absolute Benefit of Statin Treatment for Primary or Secondary Prevention of Vascular Disease in Individual Elderly Patients. Clin Res Cardiol. 2017;106(1):58-68. doi: 10.1007\/s00392-016-1023-8.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"key20251119150639_B422","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/EDE.0b013e3181a39056","article-title":"Prognostic Models with Competing Risks: Methods and Application to Coronary Risk Prediction","volume":"20","author":"Wolbers","year":"2009","unstructured":"Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic Models with Competing Risks: Methods and Application to Coronary Risk Prediction. Epidemiology. 2009;20(4):555-61. doi: 10.1097\/EDE.0b013e3181a39056.","journal-title":"Epidemiology"},{"issue":"6","key":"key20251119150639_B423","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1067\/mem.2001.119456","article-title":"Polypharmacy, Adverse Drug-Related Events, and Potential Adverse Drug Interactions in Elderly Patients Presenting to an Emergency Department","volume":"38","author":"Hohl","year":"2001","unstructured":"Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, Adverse Drug-Related Events, and Potential Adverse Drug Interactions in Elderly Patients Presenting to an Emergency Department. Ann Emerg Med. 2001;38(6):666-71. doi: 10.1067\/mem.2001.119456.","journal-title":"Ann Emerg Med"},{"issue":"9","key":"key20251119150639_B424","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/pds.1984","article-title":"Adverse Drug Events in the Outpatient Setting: An 11-Year National Analysis","volume":"19","author":"Bourgeois","year":"2010","unstructured":"Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse Drug Events in the Outpatient Setting: An 11-Year National Analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901-10. doi: 10.1002\/pds.1984.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"key20251119150639_B425","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/oxfordjournals.aje.a116963","article-title":"Prevalence of Subclinical Atherosclerosis and Cardiovascular Disease and Association with Risk Factors in the Cardiovascular Health Study","volume":"139","author":"Kuller","year":"1994","unstructured":"Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O\u2019Leary D, et al. Prevalence of Subclinical Atherosclerosis and Cardiovascular Disease and Association with Risk Factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139(12):1164-79. doi: 10.1093\/oxfordjournals.aje.a116963.","journal-title":"Am J Epidemiol"},{"issue":"9279","key":"key20251119150639_B426","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(01)05553-2","article-title":"Cholesterol and All-Cause Mortality in Elderly People from the Honolulu Heart Program: A Cohort Study","volume":"358","author":"Schatz","year":"2001","unstructured":"Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and All-Cause Mortality in Elderly People from the Honolulu Heart Program: A Cohort Study. Lancet. 2001;358(9279):351-5. doi: 10.1016\/S0140-6736(01)05553-2.","journal-title":"Lancet"},{"issue":"10","key":"key20251119150639_B427","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-126-10-199705150-00001","article-title":"Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons","volume":"126","author":"Corti","year":"1997","unstructured":"Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, et al. Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons. Ann Intern Med. 1997;126(10):753-60. doi: 10.7326\/0003-4819-126-10-199705150-00001.","journal-title":"Ann Intern Med"},{"issue":"12","key":"key20251119150639_B428","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.162.12.1395","article-title":"Therapy with Hydroxymethylglutaryl Coenzyme a Reductase Inhibitors (Statins) and Associated risk of Incident Cardiovascular Events in Older Adults: Evidence from the Cardiovascular Health Study","volume":"162","author":"Lemaitre","year":"2002","unstructured":"Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with Hydroxymethylglutaryl Coenzyme a Reductase Inhibitors (Statins) and Associated risk of Incident Cardiovascular Events in Older Adults: Evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162(12):1395-400. doi: 10.1001\/archinte.162.12.1395.","journal-title":"Arch Intern Med"},{"issue":"9602","key":"key20251119150639_B429","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood Cholesterol and Vascular Mortality by Age, Sex, and Blood Pressure: A Meta-Analysis of Individual Data from 61 Prospective Studies with 55,000 Vascular Deaths","volume":"370","author":"Prospective Studies Collaboration","year":"2007","unstructured":"Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood Cholesterol and Vascular Mortality by Age, Sex, and Blood Pressure: A Meta-Analysis of Individual Data from 61 Prospective Studies with 55,000 Vascular Deaths. Lancet. 2007;370(9602):1829-39. doi: 10.1016\/S0140-6736(07)61778-4.","journal-title":"Lancet"},{"issue":"9346","key":"key20251119150639_B430","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomised Controlled Trial","volume":"360","author":"Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomised Controlled Trial. Lancet. 2002;360(9346):1623-30. doi: 10.1016\/s0140-6736(02)11600-x.","journal-title":"Lancet"},{"issue":"9411","key":"key20251119150639_B431","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of Cholesterol-Lowering with Simvastatin on Stroke and other Major Vascular Events in 20536 People with Cerebrovascular Disease or other High-Risk Conditions","volume":"363","author":"Collins","year":"2004","unstructured":"Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of Cholesterol-Lowering with Simvastatin on Stroke and other Major Vascular Events in 20536 People with Cerebrovascular Disease or other High-Risk Conditions. Lancet. 2004;363(9411):757-67. doi: 10.1016\/S0140-6736(04)15690-0.","journal-title":"Lancet"},{"issue":"8","key":"key20251119150639_B432","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for Primary Prevention in Older Persons with Elevated C-Reactive Protein and low To Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial","volume":"152","author":"Glynn","year":"2010","unstructured":"Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for Primary Prevention in Older Persons with Elevated C-Reactive Protein and low To Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. Ann Intern Med. 2010;152(8):488-96. doi: 10.7326\/0003-4819-152-8-201004200-00005.","journal-title":"Ann Intern Med"},{"issue":"21","key":"key20251119150639_B433","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-31. doi: 10.1056\/NEJMoa1600176.","journal-title":"N Engl J Med"},{"issue":"12","key":"key20251119150639_B434","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimiba Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial","volume":"140","author":"Ouchi","year":"2019","unstructured":"Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimiba Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019;140(12):992-1003. doi: 10.1161\/CIRCULATIONAHA.118.039415.","journal-title":"Circulation"},{"issue":"22","key":"key20251119150639_B435","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036357","article-title":"Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People","volume":"13","author":"Zoungas","year":"2024","unstructured":"Zoungas S, Moran C, Curtis AJ, Spark S, Flanagan Z, Beilin L, et al. Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People. J Am Heart Assoc. 2024;13(22):e036357. doi: 10.1161\/JAHA.124.036357.","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"key20251119150639_B436","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/jama.2016.16650","article-title":"Lipid Disorders: Screening and Treatment","volume":"316","author":"Jin","year":"2016","unstructured":"Jin J. Lipid Disorders: Screening and Treatment. JAMA. 2016 Nov 15;316(19):2056. doi: 10.1001\/jama.2016.16650. PMID: 27838718..","journal-title":"JAMA"},{"issue":"Suppl 5","key":"key20251119150639_B437","first-page":"S213","article-title":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report","volume":"5","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute","year":"2011","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics. 2011;5(Suppl 5)S213-56. doi: 10.1542\/peds.2009-2107C.","journal-title":"Pediatrics"},{"issue":"4","key":"key20251119150639_B438","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MOP.0000000000001460","article-title":"Recent Updates on the Screening, Diagnosis, and Management of Lipids Disorders in Children and Adolescents","volume":"37","author":"Drastal","year":"2025","unstructured":"Drastal MS, Ferranti S, Gooding H. Recent Updates on the Screening, Diagnosis, and Management of Lipids Disorders in Children and Adolescents. Curr Opin Pediatr. 2025;37(4):325-332. doi: 10.1097\/MOP.0000000000001460.","journal-title":"Curr Opin Pediatr"},{"issue":"20","key":"key20251119150639_B439","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects","volume":"75","author":"Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol. 2020;75(20):2553-66. doi: 10.1016\/j.jacc.2020.03.057.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20251119150639_B440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The Complex Molecular Genetics of Familial Hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","unstructured":"Berberich AJ, Hegele RA. The Complex Molecular Genetics of Familial Hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9-20. doi: 10.1038\/s41569-018-0052-6.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"key20251119150639_B441","article-title":"Statins for Children with Familial Hypercholesterolemia","volume":"7","author":"Vuorio","year":"2017","unstructured":"Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for Children with Familial Hypercholesterolemia. Cochrane Database Syst Rev. 2017;7(7):CD006401. doi: 10.1002\/14651858.CD006401.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"key20251119150639_B442","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, Groot E, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-56. doi: 10.1056\/NEJMoa1816454.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20251119150639_B443","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and Safety of Ezetimiba Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","unstructured":"Kusters DM, Caceres M, Coll M, Cuffie C, Gagn\u00e9 C, Jacobson MS, et al. Efficacy and Safety of Ezetimiba Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. J Pediatr. 2015;166(6):1377-84. doi: 10.1016\/j.jpeds.2015.02.043.","journal-title":"J Pediatr"},{"issue":"10","key":"key20251119150639_B444","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S2213-8587(22)00221-2","article-title":"Paediatric Patients with Heterozygous Familial Hypercholesterolaemia Treated with Evolocumab for 80 Weeks (HAUSER-OLE): A Single-Arm, Multicentre, Open-Label Extension of HAUSER-RCT","volume":"10","author":"Santos","year":"2022","unstructured":"Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, et al. Paediatric Patients with Heterozygous Familial Hypercholesterolaemia Treated with Evolocumab for 80 Weeks (HAUSER-OLE): A Single-Arm, Multicentre, Open-Label Extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732-740. doi: 10.1016\/S2213-8587(22)00221-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"key20251119150639_B445","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11883-024-01237-z","article-title":"Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia","volume":"26","author":"Gagnon","year":"2024","unstructured":"Gagnon CA, Ashraf AP. Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia. Curr Atheroscler Rep. 2024;26(11):617-28. doi: 10.1007\/s11883-024-01237-z.","journal-title":"Curr Atheroscler Rep"},{"issue":"14","key":"key20251119150639_B446","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/jcm11144080","article-title":"Dyslipidemia in Transplant Patients: Which Therapy?","volume":"11","author":"Iannuzzo","year":"2022","unstructured":"Iannuzzo G, Cuomo G, Di Lorenzo A, Tripaldella M, Mallardo V, Idelson PI, et al. Dyslipidemia in Transplant Patients: Which Therapy? J Clin Med. 2022;11(14):4080. doi: 10.3390\/jcm11144080.","journal-title":"J Clin Med"},{"issue":"2","key":"key20251119150639_B447","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2009.02949.x","article-title":"Predicting Coronary Heart Disease after Kidney Transplantation: Patient Outcomes in Renal Transplantation (PORT) Study","volume":"10","author":"Israni","year":"2010","unstructured":"Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, et al. Predicting Coronary Heart Disease after Kidney Transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010;10(2):338-53. doi: 10.1111\/j.1600-6143.2009.02949.x.","journal-title":"Am J Transplant"},{"issue":"9","key":"key20251119150639_B448","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.healun.2006.05.001","article-title":"Multicenter Retrospective Analysis of Cardiovascular Risk Factors Affecting Long-Term Outcome of de Novo Cardiac Transplant Recipients","volume":"25","author":"Kobashigawa","year":"2006","unstructured":"Kobashigawa JA, Starling RC, Mehra MR, Kormos RL, Bhat G, Barr ML, et al. Multicenter Retrospective Analysis of Cardiovascular Risk Factors Affecting Long-Term Outcome of de Novo Cardiac Transplant Recipients. J Heart Lung Transplant. 2006;25(9):1063-9. doi: 10.1016\/j.healun.2006.05.001.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"key20251119150639_B449","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/lt.22468","article-title":"Cumulative Risk of Cardiovascular Events after Orthotopic Liver Transplantation","volume":"18","author":"Albeldawi","year":"2012","unstructured":"Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B, et al. Cumulative Risk of Cardiovascular Events after Orthotopic Liver Transplantation. Liver Transpl. 2012;18(3):370-5. doi: 10.1002\/lt.22468.","journal-title":"Liver Transpl"},{"issue":"9","key":"key20251119150639_B450","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.healun.2011.04.008","article-title":"Diverse Morphologic Manifestations of Cardiac Allograft Vasculopathy: A Pathologic Study of 64 Allograft Hearts","volume":"30","author":"Lu","year":"2011","unstructured":"Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, Perens G, et al. Diverse Morphologic Manifestations of Cardiac Allograft Vasculopathy: A Pathologic Study of 64 Allograft Hearts. J Heart Lung Transplant. 2011;30(9):1044-50. doi: 10.1016\/j.healun.2011.04.008.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"key20251119150639_B451","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of Dyslipidemia in Adult Solid Organ Transplant Recipients","volume":"13","author":"Warden","year":"2019","unstructured":"Warden BA, Duell PB. Management of Dyslipidemia in Adult Solid Organ Transplant Recipients. J Clin Lipidol. 2019;13(2):231-45. doi: 10.1016\/j.jacl.2019.01.011.","journal-title":"J Clin Lipidol"},{"issue":"21","key":"key20251119150639_B452","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis Jbet al. Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2016;134(21):468-95. doi: 10.1161\/CIR.0000000000000456.","journal-title":"Circulation"},{"issue":"6","key":"key20251119150639_B453","first-page":"639","article-title":"Choosing Statins: A Review to Guide Clinical Practice","volume":"64","author":"Borges","year":"2021","unstructured":"Borges RP, Degobi NAH, Bertoluci MC. Choosing Statins: A Review to Guide Clinical Practice. Arch Endocrinol Metab. 2021;64(6):639-53. doi: 10.20945\/2359-3997000000306.","journal-title":"Arch Endocrinol Metab"},{"issue":"5","key":"key20251119150639_B454","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with Elevated Liver Enzymes are not at Higher Risk for Statin Hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with Elevated Liver Enzymes are not at Higher Risk for Statin Hepatotoxicity. Gastroenterology. 2004;126(5):1287-92. doi: 10.1053\/j.gastro.2004.02.015.","journal-title":"Gastroenterology"},{"issue":"2","key":"key20251119150639_B455","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","unstructured":"Bj\u00f6rnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing. J Hepatol. 2012;56(2):374-80. doi: 10.1016\/j.jhep.2011.07.023.","journal-title":"J Hepatol"},{"issue":"8","key":"key20251119150639_B456","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cgh.2018.04.023","article-title":"Treatment of Dyslipidemia in Common Liver Diseases","volume":"16","author":"Speliotes","year":"2018","unstructured":"Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol. 2018;16(8):1189-96. doi: 10.1016\/j.cgh.2018.04.023.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"key20251119150639_B457","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"4","key":"key20251119150639_B458","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tcm.2025.01.001","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System","volume":"35","author":"Manolis","year":"2025","unstructured":"Manolis AA, Manolis TA, Vouliotis A, Manolis AS. Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System. Trends Cardiovasc Med. 2025;35(4):258-65. doi: 10.1016\/j.tcm.2025.01.001.","journal-title":"Trends Cardiovasc Med"},{"issue":"11","key":"key20251119150639_B459","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-Term Liver-Related Outcomes and Liver Stiffness Progression of Statin Usage in Steatotic Liver Disease","volume":"73","author":"Zhou","year":"2024","unstructured":"Zhou XD, Kim SU, Yip TC, Petta S, Nakajima A, Tsochatzis E, et al. Long-Term Liver-Related Outcomes and Liver Stiffness Progression of Statin Usage in Steatotic Liver Disease. Gut. 2024;73(11):1883-92. doi: 10.1136\/gutjnl-2024-333074.","journal-title":"Gut"},{"issue":"3","key":"key20251119150639_B460","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biom15030324","article-title":"Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment","volume":"15","author":"Zisis","year":"2025","unstructured":"Zisis M, Chondrogianni ME, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, et al. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules. 2025;15(3):324. doi: 10.3390\/biom15030324.","journal-title":"Biomolecules"},{"issue":"1","key":"key20251119150639_B461","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. doi: 10.1002\/hep.30145.","journal-title":"Hepatology"},{"issue":"3","key":"key20251119150639_B462","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","article-title":"Atorvastatin in Patients with Primary Biliary Cirrhosis and Incomplete Biochemical Response to Ursodeoxycholic Acid","volume":"46","author":"Stojakovic","year":"2007","unstructured":"Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in Patients with Primary Biliary Cirrhosis and Incomplete Biochemical Response to Ursodeoxycholic Acid. Hepatology. 2007;46(3):776-84. doi: 10.1002\/hep.21741.","journal-title":"Hepatology"},{"issue":"6","key":"key20251119150639_B463","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","article-title":"Emerging Role of Statin Therapy in the Prevention and Management of Cirrhosis, Portal Hypertension, and HCC","volume":"78","author":"Sharpton","year":"2023","unstructured":"Sharpton SR, Loomba R. Emerging Role of Statin Therapy in the Prevention and Management of Cirrhosis, Portal Hypertension, and HCC. Hepatology. 2023;78(6):1896-906. doi: 10.1097\/HEP.0000000000000278.","journal-title":"Hepatology"},{"issue":"5","key":"key20251119150639_B464","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease","volume":"161","author":"Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong V, Wright E, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-69. doi: 10.1053\/j.gastro.2021.07.049.","journal-title":"Gastroenterology"},{"issue":"6","key":"key20251119150639_B465","doi-asserted-by":"crossref","first-page":"1693.e12","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis","volume":"156","author":"Kaplan","year":"2019","unstructured":"Kaplan DE, Serper MA, Mehta R, Fox R, John B, Aytaman A, et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology. 2019;156(6):1693-1706.e12. doi: 10.1053\/j.gastro.2019.01.026.","journal-title":"Gastroenterology"},{"issue":"5","key":"key20251119150639_B466","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.amjcard.2005.04.029","article-title":"Effect of Statin Use within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortality","volume":"96","author":"Fonarow","year":"2005","unstructured":"Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of Statin Use within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortality. Am J Cardiol. 2005;96(5):611-6. doi: 10.1016\/j.amjcard.2005.04.029.","journal-title":"Am J Cardiol"},{"issue":"15","key":"key20251119150639_B467","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2007.11.075","article-title":"Lipid Levels after Acute Coronary Syndromes","volume":"51","author":"Pitt","year":"2008","unstructured":"Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid Levels after Acute Coronary Syndromes. J Am Coll Cardiol. 2008;51(15):1440-5. doi: 10.1016\/j.jacc.2007.11.075.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"key20251119150639_B468","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive Early and Sustained Lowering of Non-High-Density Lipoprotein Cholesterol after Myocardial Infarction and Prognosis: The SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","unstructured":"Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, et al. Intensive Early and Sustained Lowering of Non-High-Density Lipoprotein Cholesterol after Myocardial Infarction and Prognosis: The SWEDEHEART registry. Eur Heart J. 2024;45(39):4204-4215. doi: 10.1093\/eurheartj\/ehae576.","journal-title":"Eur Heart J"},{"issue":"13","key":"key20251119150639_B469","first-page":"771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):771-862. doi: 10.1161\/CIR.0000000000001309.","journal-title":"Circulation"},{"issue":"19","key":"key20251119150639_B470","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/eurheartj\/ehab771","article-title":"Extreme Cardiovascular Risk-Do we Need a New Risk Category?","volume":"43","author":"Dyrbu\u015b","year":"2022","unstructured":"Dyrbu\u015b K, G\u0105sior M, Penson PE, Banach M. Extreme Cardiovascular Risk-Do we Need a New Risk Category? Eur Heart J. 2022;43(19):1784-6. doi: 10.1093\/eurheartj\/ehab771.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20251119150639_B471","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR Recommendations for Cardiovascular Disease Risk Management in Patients with Rheumatoid Arthritis and other Forms of Inflammatory Joint Disorders: 2015\/2016 Update","volume":"76","author":"Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR Recommendations for Cardiovascular Disease Risk Management in Patients with Rheumatoid Arthritis and other Forms of Inflammatory Joint Disorders: 2015\/2016 Update. Ann Rheum Dis. 2017;76(1):17-28. doi: 10.1136\/annrheumdis-2016-209775.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"key20251119150639_B472","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/ATVBAHA.124.319983","article-title":"Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay","volume":"44","author":"Wilkinson","year":"2024","unstructured":"Wilkinson MJ, Shapiro MD. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay. Arterioscler Thromb Vasc Biol. 2024;44(12):2396-406. doi: 10.1161\/ATVBAHA.124.319983.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"key20251119150639_B473","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12026-016-8892-9","article-title":"Dyslipidemia in Systemic Lupus Erythematosus","volume":"65","author":"Szab\u00f3","year":"2017","unstructured":"Szab\u00f3 MZ, Szodoray P, Kiss E. Dyslipidemia in Systemic Lupus Erythematosus. Immunol Res. 2017;65(2):543-50. doi: 10.1007\/s12026-016-8892-9.","journal-title":"Immunol Res"},{"issue":"6","key":"key20251119150639_B474","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR Recommendations for Cardiovascular Risk Management in Rheumatic and Musculoskeletal Diseases, Including Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"81","author":"Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR Recommendations for Cardiovascular Risk Management in Rheumatic and Musculoskeletal Diseases, Including Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Ann Rheum Dis. 2022;81(6):768-79. doi: 10.1136\/annrheumdis-2021-221733.","journal-title":"Ann Rheum Dis"},{"issue":"7855","key":"key20251119150639_B475","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The Changing Landscape of Atherosclerosis","volume":"592","author":"Libby","year":"2021","unstructured":"Libby P. The Changing Landscape of Atherosclerosis. Nature. 2021;592(7855):524-33. doi: 10.1038\/s41586-021-03392-8.","journal-title":"Nature"},{"issue":"1","key":"key20251119150639_B476","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2013.09.006","article-title":"Cardiovascular Risk in Rheumatoid Arthritis: How to Lower the Risk?","volume":"231","author":"van Breukelen-van der Stoep","year":"2013","unstructured":"van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JM, Cabezas MC. Cardiovascular Risk in Rheumatoid Arthritis: How to Lower the Risk? Atherosclerosis. 2013;231(1):163-72. doi: 10.1016\/j.atherosclerosis.2013.09.006.","journal-title":"Atherosclerosis"},{"issue":"20","key":"key20251119150639_B477","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1161\/CIRCULATIONAHA.124.072756","article-title":"Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial","volume":"151","author":"Zimerman","year":"2025","unstructured":"Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, et al. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025;151(20):1467-76. doi: 10.1161\/CIRCULATIONAHA.124.072756.","journal-title":"Circulation"},{"issue":"39","key":"key20251119150639_B478","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1093\/eurheartj\/ehad472","article-title":"Women, Lipids, and Atherosclerotic cardiovascular Disease: A Call to Action from the European Atherosclerosis Society","volume":"44","author":"van Lennep","year":"2023","unstructured":"van Lennep JER, Tokg\u00f6zo\u011flu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, et al. Women, Lipids, and Atherosclerotic cardiovascular Disease: A Call to Action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. doi: 10.1093\/eurheartj\/ehad472.","journal-title":"Eur Heart J"},{"issue":"2","key":"key20251119150639_B479","doi-asserted-by":"crossref","first-page":"150.e1","DOI":"10.1016\/j.ajog.2019.03.025","article-title":"Is Maternal Lipid Profile in Early Pregnancy Associated with Pregnancy Complications and Blood Pressure in Pregnancy and Long Term Postpartum?","volume":"221","author":"Adank","year":"2019","unstructured":"Adank MC, Benschop L, Peterbroers KR, Gregoor AMS, Kors AW, Mulder MT, et al. Is Maternal Lipid Profile in Early Pregnancy Associated with Pregnancy Complications and Blood Pressure in Pregnancy and Long Term Postpartum? Am J Obstet Gynecol. 2019;221(2):150.e1-150.e13. doi: 10.1016\/j.ajog.2019.03.025.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"key20251119150639_B480","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tjog.2016.07.012","article-title":"Maternal Dyslipidemia During Pregnancy May Increase the Risk of Preterm Birth: A Meta-Analysis","volume":"56","author":"Jiang","year":"2017","unstructured":"Jiang S, Jiang J, Xu H, Wang S, Liu Z, Li M, Let al. Maternal Dyslipidemia During Pregnancy May Increase the Risk of Preterm Birth: A Meta-Analysis. Taiwan J Obstet Gynecol. 2017;56(1):9-15. doi: 10.1016\/j.tjog.2016.07.012.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"2","key":"key20251119150639_B481","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2006.01.002","article-title":"Marked Changes in Plasma Lipids and Lipoproteins During Pregnancy in Women with Familial Hypercholesterolemia","volume":"189","author":"Amundsen","year":"2006","unstructured":"Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, et al. Marked Changes in Plasma Lipids and Lipoproteins During Pregnancy in Women with Familial Hypercholesterolemia. Atherosclerosis. 2006;189(2):451-7. doi: 10.1016\/j.atherosclerosis.2006.01.002.","journal-title":"Atherosclerosis"},{"issue":"6","key":"key20251119150639_B482","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of Familial Hypercholesterolemia in Pregnancy","volume":"32","author":"Graham","year":"2021","unstructured":"Graham DF, Raal FJ. Management of Familial Hypercholesterolemia in Pregnancy. Curr Opin Lipidol. 2021;32(6):370-7. doi: 10.1097\/MOL.0000000000000790.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"key20251119150639_B483","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae032","article-title":"Dyslipidaemia Management in Pregnant Patients: A 2024 Update","volume":"4","author":"Lewek","year":"2024","unstructured":"Lewek J, Bielecka-D\u0105browa A, Toth PP, Banach M. Dyslipidaemia Management in Pregnant Patients: A 2024 Update. Eur Heart J Open. 2024;4(3):oeae032. doi: 10.1093\/ehjopen\/oeae032.","journal-title":"Eur Heart J Open"},{"issue":"2","key":"key20251119150639_B484","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jjcc.2012.09.009","article-title":"The Current Status of Lipoprotein (a) in Pregnancy: A Literature Review","volume":"61","author":"Fanshawe","year":"2013","unstructured":"Fanshawe AE, Ibrahim M. The Current Status of Lipoprotein (a) in Pregnancy: A Literature Review. J Cardiol. 2013;61(2):99-106. doi: 10.1016\/j.jjcc.2012.09.009.","journal-title":"J Cardiol"},{"issue":"15","key":"key20251119150639_B485","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central Nervous System and Limb Anomalies in Case Reports of First-Trimester Statin Exposure","volume":"350","author":"Edison","year":"2004","unstructured":"Edison RJ, Muenke M. Central Nervous System and Limb Anomalies in Case Reports of First-Trimester Statin Exposure. N Engl J Med. 2004;350(15):1579-82. doi: 10.1056\/NEJM200404083501524.","journal-title":"N Engl J Med"},{"key":"key20251119150639_B486","volume-title":"FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins during Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins [Internet]","author":"US Food and Drug Administration","year":"2021","unstructured":"US Food and Drug Administration. FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins during Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins [Internet]. Silver Spring: FDA; 2021 [cited 2025 Aug 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy."},{"issue":"3","key":"key20251119150639_B487","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/erc.11.196","article-title":"Statin Use During Pregnancy: A Systematic Review and Meta-Analysis","volume":"10","author":"Kusters","year":"2012","unstructured":"Kusters DM, Lahsinoui HH, van de Post JA, Wiegman A, Wijburg FA, Kastelein JJ, et al. Statin Use During Pregnancy: A Systematic Review and Meta-Analysis. Expert Rev Cardiovasc Ther. 2012;10(3):363-78. doi: 10.1586\/erc.11.196.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"key20251119150639_B488","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/17474108.2013.842684","article-title":"Are Statins Teratogenic in Humans? Addressing the Safety of Statins in Light of Potential Benefits during Pregnancy","volume":"8","author":"Zarek","year":"2013","unstructured":"Zarek J, Koren G, Nordeng H, Einarson A, Berard A, Nickel C, et al. Are Statins Teratogenic in Humans? Addressing the Safety of Statins in Light of Potential Benefits during Pregnancy. Expert Rev Obstet Gynecol. 2013;8(6):513-24. doi:10.1586\/17474108.2013.859809.","journal-title":"Expert Rev Obstet Gynecol"},{"key":"key20251119150639_B489","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and Congenital Malformations: Cohort Study","volume":"350","author":"Bateman","year":"2015","unstructured":"Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and Congenital Malformations: Cohort Study. BMJ. 2015;350:h1035. doi: 10.1136\/bmj.h1035.","journal-title":"BMJ"},{"issue":"12","key":"key20251119150639_B490","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41321","article-title":"Perinatal Outcomes After Statin Exposure During Pregnancy","volume":"4","author":"Chang","year":"2021","unstructured":"Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA Netw Open. 2021;4(12):e2141321. doi: 10.1001\/jamanetworkopen.2021.41321.","journal-title":"JAMA Netw Open"},{"key":"key20251119150639_B491","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2018.05.038","article-title":"Statins and Other Lipid-Lowering Therapy and Pregnancy Outcomes in Homozygous Familial Hypercholesterolaemia: A Retrospective Review of 39 Pregnancies","volume":"277","author":"Botha","year":"2018","unstructured":"Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and Other Lipid-Lowering Therapy and Pregnancy Outcomes in Homozygous Familial Hypercholesterolaemia: A Retrospective Review of 39 Pregnancies. Atherosclerosis. 2018;277:502-7. doi: 10.1016\/j.atherosclerosis.2018.05.038.","journal-title":"Atherosclerosis"},{"issue":"2","key":"key20251119150639_B492","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1471-0528.1995.tb09077.x","article-title":"Severe Fetal Intracranial Haemorrhage during Treatment with Cholestyramine For Intrahepatic Cholestasis of Pregnancy","volume":"102","author":"Sadler","year":"1995","unstructured":"Sadler LC, Lane M, North R. Severe Fetal Intracranial Haemorrhage during Treatment with Cholestyramine For Intrahepatic Cholestasis of Pregnancy. Br J Obstet Gynaecol. 1995;102(2):169-70. doi: 10.1111\/j.1471-0528.1995.tb09077.x.","journal-title":"Br J Obstet Gynaecol"},{"key":"key20251119150639_B493","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2016.10.018","article-title":"Lipoprotein Apheresis is Essential for Managing Pregnancies in Patients with Homozygous Familial Hypercholesterolemia: Seven Case Series and Discussion","volume":"254","author":"Ogura","year":"2016","unstructured":"Ogura M, Makino H, Kamiya C, Yoshimatsu J, Soran H, Eatough R, et al. Lipoprotein Apheresis is Essential for Managing Pregnancies in Patients with Homozygous Familial Hypercholesterolemia: Seven Case Series and Discussion. Atherosclerosis. 2016;254:179-83. doi: 10.1016\/j.atherosclerosis.2016.10.018.","journal-title":"Atherosclerosis"},{"issue":"23","key":"key20251119150639_B494","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1161\/CIR.0000000000000772","article-title":"Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement from the American Heart Association","volume":"141","author":"Mehta","year":"2020","unstructured":"Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement from the American Heart Association. Circulation. 2020;141(23):e884-e903. doi: 10.1161\/CIR.0000000000000772.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"key20251119150639_B495","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0263-2021","article-title":"Burden of Cardiovascular Diseases Attributable to Risk Factors in Brazil: Data from the \"Global Burden of Disease 2019\" Study","volume":"55","author":"Brant","year":"2022","unstructured":"Brant LCC, Nascimento BR, Veloso GA, Gomes CS, Polanczyk C, Oliveira GMM, et al. Burden of Cardiovascular Diseases Attributable to Risk Factors in Brazil: Data from the \"Global Burden of Disease 2019\" Study. Rev Soc Bras Med Trop. 2022;55(Suppl 1):e0263. doi: 10.1590\/0037-8682-0263-2021.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"8","key":"key20251119150639_B496","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCRESAHA.116.307547","article-title":"Cardiovascular Disease in Women: Clinical Perspectives","volume":"118","author":"Garcia","year":"2016","unstructured":"Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular Disease in Women: Clinical Perspectives. Circ Res. 2016;118(8):1273-93. doi: 10.1161\/CIRCRESAHA.116.307547.","journal-title":"Circ Res"},{"issue":"9","key":"key20251119150639_B497","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-020-00864-6","article-title":"The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women","volume":"22","author":"Freaney","year":"2020","unstructured":"Freaney PM, Khan SS, Lloyd-Jones DM, Stone NJ. The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. Curr Atheroscler Rep. 2020;22(9):46. doi: 10.1007\/s11883-020-00864-6.","journal-title":"Curr Atheroscler Rep"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:07:39Z","timestamp":1763564859000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/diretriz-brasileira-de-dislipidemias-e-prevencao-da-aterosclerose-2025\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":497,"journal-issue":{"issue":"09","published-print":{"date-parts":[[2025,10,13]]}},"alternative-id":["10.36660\/abc.20250640 10.36660\/abc.20250640i"],"URL":"https:\/\/doi.org\/10.36660\/abc.20250640","relation":{"has-translation":[{"id-type":"doi","id":"10.36660\/abc.20250640i","asserted-by":"object"}]},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20250640"}}